Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 1530. Отображено 100.
09-08-2012 дата публикации

Therapeutic isoxazole compounds

Номер: US20120202786A1
Принадлежит: Dart Neuroscience Cayman Ltd

The invention provides a compound of formula I: wherein A 1 , A 2 , A 3 , R 1 , X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of monoamine oxidase B (MAO-B) enzyme function and are useful for improving cognitive function and for treating psychiatric disorders in animals.

Подробнее
11-10-2012 дата публикации

Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides

Номер: US20120259120A1
Принадлежит: Thimma Rawalpally, Thomas Cleary, Yaohui Ji

The present invention provides novel methods for preparing 5-(trifluoromethoxy)-1H-3-indazolecarboxylic acid (3), which is a useful precursor for the preparation of bicyclic-5-trifluoromethoxy-1H-indazole-3-carboxylic acid amides of Formula (1). Compounds of Formula (1) are active as agonists and partial agonists of the nicotinic α-7 receptor and are being studied for their use in the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain, such as for the treatment of Alzheimer's disease and schizophrenia, as well as other psychiatric and neurological disorders. The present methods are useful for preparing compound (3) on scale up levels.

Подробнее
28-03-2013 дата публикации

NOVEL PALONOSETRON SALTS AND PROCESSES FOR PREPARATION AND PURIFICATION THEREOF

Номер: US20130079521A1
Принадлежит: CHEMAGIS LTD.

Provided are novel salts of 2-(1-azabicyclo-[2.2.2]oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one, methods of using such salts, and processes for producing such salts. 1. (canceled)2. A method of preparing pure palonosetron or a salt thereof , the method comprising:(a) dissolving or partially dissolving impure palonosetron in an organic solvent;(b) optionally cooling the solution or partial solution of step (a) to a temperature below 20° C.;(c) admixing an acid and the solution of step (a) or step (b) to form crystals of a pure palonosetron salt, which is different from the HCl salt, and(d) optionally converting the pure palonosetron salt into the free base, wherein the impure palonosetron has a purity of up to 99.1% and an isomer ratio of up to 97:3 (3S),(3aS) isomer:(3S),(3aR) isomer, and the pure palonosetron or salt thereof has a purity of at least 99.5% and a (3S),(3aS):(3S),(3aR) isomer ratio of 99:1 or greater.3. The method of claim 2 , further comprising isolating the crystals.4. The method of claim 2 , wherein the organic solvent is selected from the group consisting of methanol claim 2 , ethanol claim 2 , n-propanol claim 2 , isopropanol claim 2 , and mixtures thereof.5. The method of claim 4 , wherein the organic solvent is ethanol.6. The method of claim 2 , wherein the acid of step (c) is selected from oxalic acid claim 2 , benzoic acid claim 2 , maleic acid claim 2 , malonic acid claim 2 , fumaric acid claim 2 , tartaric acid claim 2 , succinic acid claim 2 , citric acid claim 2 , methanesulfonic acid claim 2 , hydrobromic acid claim 2 , phosphoric acid claim 2 , and mixtures thereof.721-. (canceled) This patent application claims the benefit of U.S. Provisional Patent Application No. 60/932,139, filed May 29, 2007, which is incorporated herein by reference.The present invention relates to organic chemistry and more particularly to processes for preparation and purification of palonosetron and salts thereof.Palonosetron, 2-(1-azabicyclo-[ ...

Подробнее
16-05-2013 дата публикации

NOVEL PROCESS FOR THE PREPARATION OF SOLIFENACIN SUCCINATE

Номер: US20130123502A1
Принадлежит:

The present invention relates to a process for the preparation of Solifenacin succinate by condensing a compound of formula (IVb) with (RS)-3-quinuclidinol, wherein, R represents methyl, ethyl, isopropyl; to produce a diastereomeric mixture of (1S)-3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylic acid (3RS)-1-azabicyclo[2.2.2]oct-3-yl ester, which is treated with succinic acid in a solvent or mixture of solvents to produce optically pure Solifenacin succinate, Formula (X). 2. The process according to claim 1 , wherein the process of step-(i) is carried out in the presence of a base in a solvent.3. The process according to claim 2 , wherein the base used in step-(i) is selected from inorganic base such as sodium hydride claim 2 , potassium hydride claim 2 , sodium hydroxide claim 2 , potassium hydroxide claim 2 , lithium hydroxide claim 2 , sodium carbonate claim 2 , potassium carbonate and the organic base such as an amine claim 2 , for example diethylamine claim 2 , triethylamine claim 2 , diisopropylethylamine claim 2 , tert-butylamine claim 2 , pyridine.4. The process according to claim 2 , wherein the solvent used in step-(i) is selected from acetonitrile claim 2 , cyclic or acyclic alkanes such as hexane claim 2 , heptane claim 2 , methylcyclohexane claim 2 , aromatic solvents such as toluene claim 2 , halogenated solvents such as dichloromethane (MDC) claim 2 , dichloroethane claim 2 , chloroform claim 2 , esters such as ethyl acetate claim 2 , butyl acetate claim 2 , isopropyl acetate or ethers such as diethyl ether claim 2 , tetrahydrofuran or tert-butyl methyl ether and/or mixtures thereof.5. The process according to claim 1 , wherein the solvent used in step-(ii) is selected from methanol claim 1 , ethanol claim 1 , isopropanol claim 1 , ethyl acetate or mixtures there of.6. The process according to claim 1 , wherein the process is carried out in a single step without isolating diastereomeric mixture of Solifenacin.8. The process according to claim 7 , ...

Подробнее
06-06-2013 дата публикации

HETEROARYL CARBOXAMIDES

Номер: US20130144062A1
Принадлежит: Bayer Pharma AG

The invention relates to novel heteroaryl carboxamides, a process for their preparation, and pharmaceutical compositions containing them. These materials are useful for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory. 5) A compound having the IUPAC name:N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-quinolinecarboxamide hydrochloride;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-phenazinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-7-quinolinecarboxamide hydrochloride;N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-quinolinecarboxamide hydrochloride;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-7-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-6-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-methyl-7-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-methyl-6-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-4-methyl-6-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-propyl-6-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-4-methyl-6-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-propyl-7-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-4-methyl-7-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-4-(tetrahydro-2H-pyran-2-yl)-6-quinoline-carboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-4-(tetrahydro-2H-pyran-2-yl)-7-quinoline-carboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-phenyl-6-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-phenyl-7-quinolinecarboxamide;or a salt thereof. This application is a Continuation application of U.S. application Ser. No. 10/496,404 filed on May 13, 2004, which is a 371 of PCT/EP02/12375 filed Nov. 6, 2002, which claims priority to German Patent Application No. 101 56 719.7 filed Nov. 19, 2001, the contents of each of which are incorporated herein by reference.The invention relates to novel heteroaryl carboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for ...

Подробнее
04-07-2013 дата публикации

QUINUCLIDINE ESTERS OF 1-AZAHETEROCYCLYLACETIC ACID AS ANTIMUSCARINIC AGENTS, PROCESS FOR THEIR PREPARATION AND MEDICINAL COMPOSITIONS THEREOF

Номер: US20130172302A1
Принадлежит: CHIESI FARMACEUTICI S.p.A.

Compounds of formula (I): 2. A compound according to wherein:{'sub': 3', '3', '4, 'A is O, S, N(R), or C(R)R,'}{'sub': 1', '6', '1', '10', '1', '10, 'R1 is aryl, aryl(C-C)alkyl, or heteroaryl, each of which may be optionally substituted by one or more substituents selected from the group consisting of a halogen atom, (C-C)alkyl, (C-C)alkoxyl, aryloxy, and heteroaryl.'}3. A compound according to claim 1 , wherein:{'sub': 3', '4, 'A is C(R)R,'}m and n are both 2,{'sub': 1', '10', '1', '10, 'R1 is aryl or heteroaryl, each of which may be optionally substituted by one or more substituents selected from the group consisting of a halogen atom, (C-C)alkyl, (C-C)alkoxyl, aryloxy, and heteroaryl;'} {'br': None, 'sub': 2', '2, 'i': p', 'q, '(CH)-P—(CH)-W\u2003\u2003(Y)'}, 'R3 is a group of formula (Y)whereinp is 0, 1, or 3,P is CO,Q is 0,{'sub': 1', '10', '1', '10', '1', '10', '1', '10, 'W is s (C-C)alkyl, aryl, or heteroaryl, each of which may be optionally substituted by one or more substituents selected from the group consisting of a halogen atom, (C-C)alkyl, (C-C)alkoxyl, OH, and (C-C)alkanoyl.'}4. A compound according to claim 1 , wherein:W is phenyl, benzothioxolyl, thiophenyl, or thiazolyl, each of which may be optionally substituted by one or more substituents selected from the group consisting of a halogen atom, OH, methyl, and acetyl.5. A compound according to claim 1 , wherein:{'sup': '−', 'X is chloride, bromide, iodide, trifluoroacetate, formate, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate, or p-toluenesulfonate.'}8. A pharmaceutical composition claim 1 , comprising a compound according to and one or more pharmaceutically acceptable carriers or excipients.9. A pharmaceutical composition according to claim 8 , which is in a form selected from the group of a powder for inhalation claim 8 , propellant-driven pressurised metered dose inhaler claim 8 , and propellant-free nebulised ...

Подробнее
04-07-2013 дата публикации

PYRIDAZINONES AS GPR119 AGONISTS

Номер: US20130172323A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to pyridazinone derivatives of general formula I, wherein the groups A, G and Rare as defined in the application, the tautomers thereof, stereoisomers thereof, the mixtures thereof and the salts thereof, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity. 8. The physiologically acceptable salts of the compounds of formula I according to .9. A medicament comprising a compound of formula I according to or a physiologically acceptable salt and an inert carriers or diluents.10. A method of treating or preventing a metabolic disease in a patient in need thereof comprising administering to the patient a compound according to .11. The compound according to claim 1 , excluding each of the compounds:5-methyl-6-[2-(3-thienyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(2-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(2-furyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(2-thienyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(3-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(2-pyrazinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(4-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(1-acetyl-piperidino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(4-methyl-5-oxazolyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(5-pyrimidinyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(2-amino-5-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,6-[2-(2-pyridyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,6-[2-(2-furyl)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(4-thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(1-piperidino)-benzoxazol-6-yl]-4,5-dihydro-3(2H)-pyridazinone,5-methyl-6-[2-(1-oxido-4-thiomorpholino)-benzoxazol-6-yl]-4,5-dihydro ...

Подробнее
18-07-2013 дата публикации

Crystalline Form of (R)-7-Chloro-N-(Quinuclidin-3-yl)benzo[B]thiophene-2-Carboxamide Hydrochloride Monohydrate

Номер: US20130183380A1
Принадлежит: EnVivo Pharmaceuticals, Inc.

Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described. 1. A crystalline Form I of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate , characterized by an x-ray powder diffraction pattern having peaks expressed as 2⊖ at one or both of 17.48 and 20.58±0.20 degrees when measured against an internal silicon standard.2. The crystalline Form I of claim 1 , characterized by an x-ray powder diffraction pattern further having at least one peak expressed as 2⊖ at 4.50 claim 1 , 9.04 claim 1 , 14.60 claim 1 , 15.14 claim 1 , 15.80 claim 1 , 16.60 claim 1 , 18.16 claim 1 , 18.44 claim 1 , 19.48 claim 1 , 21.74 claim 1 , and 25.46±0.20 degrees when measured against an internal silicon standard.3. The crystalline Form I of claim 2 , characterized by an x-ray powder diffraction pattern further having at least two peaks expressed as 2⊖ at 4.50 claim 2 , 9.04 claim 2 , 14.60 claim 2 , 15.14 claim 2 , 15.80 claim 2 , 16.60 claim 2 , 18.16 claim 2 , 18.44 claim 2 , 19.48 claim 2 , 21.74 and 25.46±0.20 degrees when measured against an internal silicon standard.4. The crystalline Form I of claim 2 , characterized by an x-ray powder diffraction pattern further having at least four peaks expressed as 2⊖ at 4.50 claim 2 , 9.04 claim 2 , 14.60 claim 2 , 15.14 claim 2 , 15.80 claim 2 , 16.60 claim 2 , 18.16 claim 2 , 18.44 claim 2 , 19.48 claim 2 , 21.74 and 25.46±0.20 degrees when measured against an internal silicon standard.5. The crystalline Form I of claim 2 , characterized by an x-ray powder diffraction pattern further having at least six peaks expressed as 2⊖ at 4.50 claim 2 , 9.04 claim 2 , 14.60 claim 2 , 15.14 claim 2 , 15.80 claim 2 , 16.60 claim 2 , 18.16 claim 2 , 18.44 claim 2 , 19.48 claim 2 , 21.74 and 25.46±0.20 degrees when measured against an internal silicon standard.6. The ...

Подробнее
08-08-2013 дата публикации

SOLIFENACIN SALTS

Номер: US20130203804A1
Принадлежит: CRYSTAL PHARMA, S.A.U.

The invention concerns fumarate salts of solifenacin, as well as pharmaceutical compositions comprising fumarate salts of solifenacin. The invention furthermore concerns a process for preparing solifenacin and salts thereof. The fumarate salt provides improved properties over the known solifenacin salts, especially in terms of its stability. The novel process for its preparation is furthermore improved over known processes for preparing solifenacin in that it provides a higher yield and recovers a greater amount of starting material. 1. A fumarate salt of solifenacin.216-. (canceled)17. The fumarate salt according to claim 1 , wherein said fumarate salt is a hydrogenfumarate (1:1) salt.18. The fumarate salt according to claim 1 , wherein said fumarate salt is substantially crystalline.19. A pharmaceutical composition comprising the fumarate salt according to and one or more pharmaceutically acceptable carriers claim 1 , wherein said pharmaceutical composition is a solid formulation.20. The pharmaceutical composition according to claim 19 , wherein said pharmaceutical composition is formulated for oral administration.21. The pharmaceutical composition according to claim 19 , wherein said pharmaceutical composition is in the form of a tablet claim 19 , a capsule claim 19 , a gelcap claim 19 , a granule claim 19 , a sachet or a pill.22. The pharmaceutical composition according to claim 21 , wherein said pharmaceutical composition is in the form of a tablet.23. A process for preparing solifenacin or a pharmaceutically acceptable salt thereof comprising:a) reacting a solifenacin base with a fumaric acid to form a fumarate salt thereof; andb) optionally transforming the fumarate salt obtained in step a) to solifenacin base and/or a different pharmaceutically acceptable salt of solifenacin.24. The process according to claim 23 , wherein step a) is preceded by the steps:a′) reacting 1(S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline with a C1-6 alkyl chloroformate to form a ...

Подробнее
22-08-2013 дата публикации

Compositions and Methods for Treatment of Neurodegenerative Disease

Номер: US20130217679A1
Принадлежит:

Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. 2. (canceled)3. The compound of claim 1 , wherein X is S(O).4. The compound of claim 1 , wherein Ris H or methyl.5. The compound of claim 1 , wherein Ris methyl or ethyl.6. The compound of claim 1 , wherein Ris methyl or ethyl.7. The compound of claim 1 , wherein the compound is a compound of formula (I) and n is one or two and each Ris methyl.8. The compound of claim 1 , wherein the compound is a compound of formula (I) and n is at least 3 claim 1 , and two occurrences of Rare gem-dimethyl groups and one occurrence of Ris oxo.9. The compound of claim 1 , wherein X is C(O) and Ris —N(RR).10. The compound of claim 9 , wherein Rand Rare each independently unsubstituted C-Calkyl.11. The compound of claim 9 , wherein Rand Rare taken together with the nitrogen atom to which they are attached to form a 4-10-membered heterocyclic ring.12. The compound of claim 1 , wherein the compound is a compound of formula (I) and Ris H and Ris —(CH)N(ethyl).14. A method of treating or preventing a neurodegenerative disease or disorder claim 1 , the method comprising administering to a subject in need thereof an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , to the subject claim 1 , thereby treating or preventing the neurodegenerative disease or disorder.15. The method of claim 14 , wherein the neurodegenerative disease or disorder is glaucoma.16. The method of claim 15 , wherein the neurodegenerative disease or disorder is glaucoma that is not neovascular glaucoma.17. The method of claim 14 , wherein the step of administering the compound includes administering the compound in a pharmaceutically acceptable composition.18. The method of claim 14 , wherein the subject is a mammal.19. The method of claim 14 , wherein the subject is a human.20. The method of claim 14 , further comprising the step of monitoring ...

Подробнее
22-08-2013 дата публикации

INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF

Номер: US20130217683A1
Принадлежит: MEMORY PHARMACEUTICALS CORPORATION

The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (e.g., indazoles and benzothiazoles), which act as ligands for the α7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof. 147-. (canceled)49. A method according to claim 48 , wherein said patient is suffering from schizophrenia claim 48 , anxiety claim 48 , mania claim 48 , depression claim 48 , manic depression claim 48 , Tourette's syndrome claim 48 , Parkinson's disease claim 48 , Huntington's disease claim 48 , Alzheimer's disease claim 48 , Lewy Body Dementia claim 48 , Amyotrophic Lateral Sclerosis claim 48 , memory impairment claim 48 , memory loss claim 48 , cognition deficit claim 48 , attention deficit claim 48 , and/or Attention Deficit Hyperactivity Disorder.52. (canceled)53. (canceled)54. (canceled)55. (canceled)56. (canceled)57. (canceled)60. A method according to claim 59 , wherein said memory impairment is due to decreased nicotinic acetylcholine receptor activity.61. (canceled)62. (canceled)63. (canceled)64. (canceled)65. (canceled)66. (canceled)68. A method according to claim 67 , wherein said inflammatory disease is rheumatoid arthritis claim 67 , diabetes or sepsis.69. A method according to claim 48 , wherein said patient is a human.70. The method according to claim 48 , wherein R′ is H or CH.71. The method according to claim 48 , wherein Ris alkynyl having 2 to 6 carbon atoms claim 48 , fluorinated hydroxyalkyl having 1 to 4 carbon atoms claim 48 , or Ar-alkynyl.72. The method according to claim 48 , wherein said compound is of formula I.73. The method according to claim 72 , wherein Ris NH claim 72 , CF claim 72 , OCH claim 72 , ...

Подробнее
29-08-2013 дата публикации

PRODUCTION PROCESS OF OPTICALLY ACTIVE 3-QUINUCLIDINOL DERIVATIVE

Номер: US20130225824A1
Принадлежит: NIPPON SODA CO., LTD.

A process is provided for efficiently producing an optically active 3-quinuclidinol derivative of high optical purity using a readily available ruthenium compound as an asymmetric reduction catalyst. This process is a process for producing an optically active 3-quinuclidinol derivative represented by the following formula (III) comprising asymmetrically hydrogenating a 3-quinuclidinone derivative represented by the following formula (I) in the presence of a ruthenium compound (II) represented by formula (II): Ru(X)(Y)(P)[RRC*(NRR)-A-RRC*(NRR)] (in the formulas, R represents a hydrogen atom or C7 to C18 aralkyl group and the like, X and Y represent hydrogen atoms or halogen atoms and the like, Px represents a phosphine ligand, n represents 1 or 2, R1 to R8 represent hydrogen atoms or C1 to C20 alkyl groups and the like, * represents an optically active carbon atom and A represents an ethylene group and the like). 15-. (canceled) The present invention relates to a process for producing optically active 3-quinuclidinol derivatives that are useful as production raw materials of physiologically active substances, and particularly pharmaceuticals.The present application claims priority on Japanese Patent Application No. 2007-230973, filed on Sep. 6, 2007, and Japanese Patent Application No. 2008-032311, filed on Feb. 13, 2008, the contents of which are incorporated herein by reference.Many alkaloids, and particularly those compounds having an azabicyclo ring structure, are useful as physiologically active substances. In particular, optically active 3-quinuclidinol derivatives are important compounds as production raw materials of pharmaceuticals.A conventionally known process for industrial production of optically active 3-quinuclidinol consists of direct asymmetric hydrogenation of 3-quinuclidinone using inexpensive hydrogen gas for the hydrogen source in the presence of an asymmetric hydrogenation catalyst (Patent Documents 1 to 4).In this production process, an ...

Подробнее
03-10-2013 дата публикации

COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE

Номер: US20130261114A1
Принадлежит:

The present invention relates to compounds useful as inhibitors of choline kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. 2. The compound of claim 1 , wherein Ris H.3. The compound according to any one of or claim 1 , wherein Ris R.4. The compound of claim 3 , wherein Ris phenyl claim 3 , a 5-6 membered monocyclic heteroaryl claim 3 , or an −8-12 membered bicyclic heteroaryl.5. The compound of claim 4 , wherein Ris phenyl claim 4 , benzothiazolyl claim 4 , pyridinyl claim 4 , indolyl claim 4 , or imidazolyl.7. The compound of claim 5 , wherein Ris phenyl or benzothiazolyl9. The compound of claim 7 , wherein Ris benzothiazolyl.11. The compound of claim 7 , wherein Ris phenyl.13. The compound according to claim 1 , wherein Jis —ORor R.14. The compound of claim 13 , wherein —Ris H.15. The compound of claim 13 , wherein —Ris R.16. The compound of claim 15 , wherein Ris —Caliphatic claim 15 , wherein up to four methylene groups may be replaced with C═O claim 15 , nitrogen claim 15 , sulfur claim 15 , or oxygen.17. The compound of claim 16 , wherein Ris substituted with at least one occurrence of W.18. The compound of claim 17 , wherein W is a −4-8 membered monocyclic heterocyclyl.19. The compound of claim 18 , wherein W is independently piperazinyl claim 18 , morpholinyl claim 18 , piperidinyl claim 18 , or pyrrolidinyl.21. The compound of claim 15 , wherein Ris independently a 5-6 membered monocyclic heteroaryl or −4-8 membered monocyclic heterocyclyl.22. The compound of claim 21 , wherein Ris a −4-8 membered monocyclic heterocyclyl.23. The compound of claim 22 , wherein Ris a pyranyl.25. The compound of claim 21 , wherein Ris a 5-6 membered monocyclic heteroaryl.26. The compound of claim 25 , wherein Ris an imidazolyl.28. The compound ...

Подробнее
24-10-2013 дата публикации

COMPOUNDS USEFUL AS INHIBITORS OF CHOLINE KINASE

Номер: US20130281445A1
Принадлежит:

The present invention relates to compounds useful as inhibitors of choline kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. 2. The compound of claim 1 , wherein n is 0.3. The compound according to any one of or claim 1 , wherein Qis independently selected from phenyl claim 1 , thiazolyl claim 1 , or pyridinyl.53. The compound according to any one of - claims 1 , wherein Qis phenyl.65. The compound according to any one of - claims 1 , wherein Jis NRR.7. The compound of claim 6 , wherein Ris Calkyl and Ris Calkyl.8. The compound according to any one of claim 6 , wherein Rand R claim 6 , taken together with the nitrogen to which they are bound claim 6 , form a 5 membered heterocyclic ring.9. The compound of claim 8 , wherein Jis pyrrolidinyl.106. The compound according to any one of - claims 1 , wherein Rand R claims 1 , taken together with the nitrogen to which they are bound claims 1 , form a 6 membered heterocyclic ring.11. The compound of claim 10 , wherein Jis piperidinyl.12. The compound according to any one of or claim 10 , wherein Jis ethyl or tert-butyl.1312. The compound according to any one of - claims 1 , wherein Qis absent.1412. The compound according to any one of - claims 1 , wherein Qis fused to Q.15. The compound of claim 14 , wherein Qis benzo.16. The compound of claim 15 , wherein Qis fused to Q1 to form naphthalene.17. The compound of claim 16 , wherein Jis Calkyl18. The compound of claim 17 , wherein Jis methyl.19. The compound of claim 14 , wherein Qis a 5 or 6 membered non-aromatic ring having 1-2 heteroatoms selected from nitrogen or oxygen.20. The compound of claim 19 , wherein Qis independently selected from pyrrolidinyl claim 19 , morpholinyl claim 19 , piperazinyl claim 19 , or dioxolyl.22. The compound of ...

Подробнее
07-11-2013 дата публикации

PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES

Номер: US20130296340A1
Принадлежит:

A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof. 17-. (canceled)9. The compound of or a pharmaceutically acceptable salt claim 8 , solvate or hydrate thereof claim 8 , wherein B is NH.10. The compound of or a pharmaceutically acceptable salt claim 8 , solvate or hydrate thereof claim 8 , wherein A is thiazolyl claim 8 , benzothiazolyl claim 8 , pyridyl claim 8 , isoxazolyl claim 8 , isoquinolinyl claim 8 , quinolyl claim 8 , benzothiadiazolyl claim 8 , thiadiazolyl claim 8 , pyrazolyl or pyrazinyl claim 8 , which is optionally substituted by at least one selected from the group consisting of halo claim 8 , chlorophenyl claim 8 , C-Calkyl claim 8 , C-Ccycloalkyl claim 8 , C-Caralkyl claim 8 , C-Calkoxy claim 8 , and C-Caryl.11. The compound of or a pharmaceutically acceptable salt claim 8 , solvate or hydrate thereof claim 8 , wherein A is thiazolyl or benzothiazolyl optionally substituted by at least one selected from the group consisting of halo claim 8 , chlorophenyl claim 8 , C-Calkyl claim 8 , C-Ccycloalkyl claim 8 , C-Caralkyl claim 8 , C-Calkoxy claim 8 , and C-Caryl.12. The compound of or a pharmaceutically acceptable salt claim 8 , solvate or hydrate thereof claim 8 , wherein A is C-Cheteroaryl substituted by at least one selected from the group consisting of chloro claim 8 , methyl claim 8 , ethyl claim 8 , propyl claim 8 , iso-propyl claim 8 , tert-butyl claim 8 , cyclopentyl claim 8 , phenyl claim 8 , chlorophenyl claim 8 , benzyl claim 8 , cyclohexyl and methoxy.13. The compound of or a pharmaceutically acceptable salt claim 8 , solvate or hydrate thereof claim 8 , wherein A is selected from thiazolyl claim 8 , methylthiazolyl claim 8 , ethylthiazolyl claim 8 , propylthiazolyl claim 8 , iso- ...

Подробнее
07-11-2013 дата публикации

VINYL QUINUCLIDINE USEFUL AS A SYNTHESIS INTERMEDIATE IN THE PREPARATION OF (R)-MEQUITAZINE

Номер: US20130296553A1
Принадлежит:

The present invention relates to the use of the vinyl quinuclidine enantiomer (R) of the following formula 2 as a synthesis intermediate in the preparation of (R)-mequitazine. 1. (canceled)4. The method according to claim 3 , wherein step (a) is carried out by ozonolysis.5. The method according to claim 3 , wherein step (a) is carried out from an acid addition salt of the (R) enantiomer of the vinyl quinuclidine of formula 2 as defined in .6. The method according to claim 3 , wherein step (b) is carried out in the presence of a hydride.7. The method according to claim 6 , wherein the hydride is NaBH.8. The method according to claim 3 , wherein R3 represents a mesylate (OMs).9. The method according to claim 8 , wherein step (c) is carried out in the presence of mesyl chloride (MsCl) and a base.10. The method according to claim 9 , wherein the base is pyridine.11. The method according to claim 3 , wherein step (d) is carried out in the presence of a base.12. The method according to claim 11 , wherein the base is potassium tert-butoxylate. The present invention relates to the optically pure vinyl quinuclidine of the following formula 2 as a synthesis intermediate in the preparation of the (R) enantiomer, dextrorotary, of the mequitazine of the following formula 1a:Mequitazine 1 is an active ingredient developed by the Pierre Fabre laboratories and commercialised in the racemic version thereof (mixture of 2 enantiomers 1a and 1b, Scheme 1) under the name of Primalan®. This medicine is used as an anti-histaminic for the treatment for example of urticaria, hay fever or certain allergies. Its preparation in the racemic form and in the levorotary form thereof 1b has been described in the patents FR 2 522 660 and EP 0 089 860. The drawback of the protocol for synthesising mequitazine in an optically active form (1a or 1b) is that it involves a step of resolution of the racemic, via the formation of a complex with tartaric acid. This resolution involves the loss of 50% at ...

Подробнее
21-11-2013 дата публикации

NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME

Номер: US20130310353A1
Принадлежит:

Provided is a pharmaceutical composition comprising: (i) 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo-[2.2.2]octane or an enantiomer, mixture of enantiomers, or a racemate thereof, wherein an anion X with a single negative charge is associated with the positive charge of the nitrogen atom; and (ii) a phosphodiesterase IV inhibitor and methods of using the same. 135-. (canceled)36. A pharmaceutical composition comprising:{'sup': '−', '(i) 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo-[2.2.2]octane or an enantiomer, mixture of enantiomers, or a racemate thereof, wherein an anion X with a single negative charge is associated with the positive charge of the nitrogen atom; and'}(ii) a phosphodiesterase IV inhibitor.37. The composition of further comprising a pharmaceutically acceptable carrier or diluent.38. The composition of wherein the anion X is chloride claim 36 , bromide claim 36 , iodide claim 36 , sulfate claim 36 , nitrate claim 36 , phosphate claim 36 , acetate claim 36 , maleate claim 36 , fumarate claim 36 , citrate claim 36 , oxalate claim 36 , succinate claim 36 , tartrate claim 36 , malate claim 36 , mandelate claim 36 , methanesulfonate claim 36 , p-toluenesulfonate claim 36 , or trifluoroacetate.39. The composition of which is suitable for inhalation.40. The composition of wherein the composition is a liquid inhalant claim 36 , powder inhalant claim 36 , or inhalation aerosol.41. The composition of further comprising a steroid.42. The composition of further comprising a βagonist.43. The composition of further comprising a βagonist.44. The composition of wherein the pharmaceutically acceptable carrier or diluent is lactose.45. A method for treating chronic obstructive pulmonary disease claim 36 , chronic bronchitis claim 36 , bronchial hyperreactivity claim 36 , asthma claim 36 , or rhinitis which method comprises administering to a human or animal patient in need of such treatment an effective ...

Подробнее
21-11-2013 дата публикации

5-HT3 RECEPTOR MODULATORS, METHODS OF MAKING, AND USE THEREOF

Номер: US20130310366A1
Принадлежит: ALBANY MOLECULAR RESEARCH, INC.

Novel 5-HTreceptor modulators are disclosed. These compounds are used in the treatment of various disorders, including chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and irritable bowel syndrome. Methods of making these compounds are also described in the present invention. 2. The compound according to in the (S) configuration.3. The compound according to in the (R) configuration.4. A pharmaceutical composition comprising a therapeutically effective amount of the compound according to and a pharmaceutically acceptable carrier.5. A method of treating irritable bowel syndrome comprising:selecting a patient with irritable bowel syndrome; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering to the patient a therapeutically effective amount of a compound according to or a pharmaceutically acceptable salt thereof.'}6. The method according to further comprising:{'sub': 3', '4, 'administering to the patient a therapeutically effective amount of a second serotonin 5-HTreceptor modulator or a serotonin 5-HTreceptor modulator.'}7. The method according to claim 6 , wherein the second serotonin 5HTreceptor modulator or serotonin 5HTreceptor modulator is selected from the group consisting of Alosetron claim 6 , renzapride claim 6 , cilansetron claim 6 , Tegaserod claim 6 , Prucalopride claim 6 , ondansetron claim 6 , somatostatin analogs claim 6 , muscarinic receptor antagonists claim 6 , laxatives claim 6 , antispasmodics claim 6 , antidepressants claim 6 , antidiarrheal agents claim 6 , prokinetic agents claim 6 , peripheral opiate narcotic antagonists claim 6 , and combinations thereof.8. A method of treating emesis comprising:selecting a patient with emesis; and{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering to the patient a therapeutically effective amount of a compound according to or a pharmaceutically acceptable salt thereof.'}9. The method according to further comprising:administering to the patient a ...

Подробнее
28-11-2013 дата публикации

PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES

Номер: US20130317059A1
Принадлежит: SK BIOPHARMACEUTICALS CO., LTD.

A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof. 17-. (canceled)9. The compound of or a pharmaceutically acceptable salt claim 8 , solvate or hydrate thereof claim 8 , wherein B is NH.10. The compound of or a pharmaceutically acceptable salt claim 8 , solvate or hydrate thereof claim 8 , wherein A is phenyl or naphthyl optionally substituted by at least one selected from the group consisting of halo claim 8 , amino claim 8 , phenyl claim 8 , C-Calkyl claim 8 , C-Calkynyl claim 8 , C-Ccycloalkyl claim 8 , C-Calkoxy claim 8 , C-Caralkoxy claim 8 , C-Caryloxy claim 8 , C-Calkylthio claim 8 , C-Caralkylthio claim 8 , C-Carylthio claim 8 , C-Calkylsulfonyl and C-Cheteroaryl.11. The compound of or a pharmaceutically acceptable salt claim 8 , solvate or hydrate thereof claim 8 , wherein A is phenyl optionally substituted by at least one selected from the group consisting of halo claim 8 , amino claim 8 , phenyl claim 8 , C-Calkyl claim 8 , C-Calkynyl claim 8 , C-Ccycloalkyl claim 8 , C-Calkoxy claim 8 , C-Caralkoxy claim 8 , C-Caryloxy claim 8 , C-Calkylthio claim 8 , C-Caralkylthio claim 8 , C-Carylthio claim 8 , C-Calkylsulfonyl and C-Cheteroaryl.12. The compound of or a pharmaceutically acceptable salt claim 8 , solvate or hydrate thereof claim 8 , wherein the compound is a compound of Formula I and A is phenyl optionally substituted by at least one selected from the group consisting of halo claim 8 , amino claim 8 , phenyl claim 8 , C-Calkyl claim 8 , C-Calkynyl claim 8 , C-Ccycloalkyl claim 8 , C-Calkoxy claim 8 , C-Caralkoxy claim 8 , C-Caryloxy claim 8 , C-Calkylthio claim 8 , C-Caralkylthio claim 8 , C-Carylthio claim 8 , C-Calkylsulfonyl and C-Cheteroaryl.13. The compound of or a pharmaceutically ...

Подробнее
02-01-2014 дата публикации

2-Phenoxy- and 2-Phenylsulfonamide Derivatives with CCR3 Antagonistic Activity for the Treatment of Inflammatory or Immunological Disorders

Номер: US20140005176A1
Принадлежит: Axikin Pharmaceuticals, Inc.

Provided herein are 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity. These compounds are useful for the treatment of diseases associated with CCR3 activity, including but not limited to, atopic dermatitis, allergic rhinitis, rheumatoid arthritis, Grave's disease, HIV infection, Alzheimer's disease, atherosclerosis and other inflammatory and/or immunological disorders. 117.-. (canceled)22. The method of claim 18 , wherein the compound claim 18 , its tautomeric or stereoisomeric form claim 18 , or a physiologically acceptable salt thereof claim 18 , is selected from the group consisting of:(R)—N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-5-cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonamide;(S)—N-(1-Aza-bicyclo[2.2.2]oct-3-yl)-5-cyano-2-(3,5-dichloro-phenoxy)-benzenesulfonamide;N-(1-aza-bicyclo[2.2.2]oct-3-yl)-2-(3,5-dichloro-phenylsulfanyl)-5-nitro-benzenesulfonamide; and(R)-5-cyano-2-(3,5-dichlorophenoxy)-N-(2-(2,5-dioxopyrrolidin-1-yl)ethyl)-N-(1-aza-bicyclo[2.2.2]oct-3-yl)benzenesulfonamide.23. The method of claim 18 , wherein the compound claim 18 , its tautomeric or stereoisomeric form claim 18 , or a physiologically acceptable salt thereof is formulated with one or more pharmaceutically acceptable excipients.24. The method of claim 23 , wherein the excipient is an inert substance selected from the group consisting of a carrier claim 23 , a diluent claim 23 , a flavoring agent claim 23 , a sweetener claim 23 , a lubricant claim 23 , a solubilizer claim 23 , a suspending agent claim 23 , a binder claim 23 , a tablet disintegrating agent and an encapsulating agent. The present invention relates to a benzenesulfonamide derivative, which is useful as an active ingredient of pharmaceutical preparations. The benzenesulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor 3) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with CCR3 activity, in particular for the treatment of ...

Подробнее
23-01-2014 дата публикации

(2S,3R)-N-(2-((3-PYRIDINYL)METHYL)-1-AZABICYCLO[2.2.2]OCT-3-YL)BENZYOFURN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF

Номер: US20140024673A1
Принадлежит: Targacept,Inc.

The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems. 1. A method for treating one or more of mild cognitive impairment , age-associated memory impairment , pre-senile dementia , early onset Alzheimer's disease , senile dementia , dementia of the Alzheimer's type , or Alzheimer's disease comprising administering a compound (2S ,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof , substantially free of (2S ,3S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide , (2R ,3S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide , (2R ,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide , and pharmaceutically acceptable salts thereof.2. The method of claim 1 , wherein the treatment is for Alzheimer's disease.3. The method of claim 1 , wherein the treatment is for early onset Alzheimer's disease. The present invention is a continuation of U.S. patent application Ser. No. 13/116,080, filed May 26, 2011, which is a continuation of U.S. patent application Ser. No. 12/184,312, filed Aug. 1, 2008, now U.S. Pat. No. 7,981,906 issued Jul. 19, 2011, which claims benefit to U.S. Provisional Application Nos. 60/971,654, filed Sep. 12, 2007, 60/953,610, filed Aug. 2, 2007, 60/953,613, filed Aug. 2, 2007, and 60/953,614 filed Aug. 2, 2007, each of which is incorporated herein by reference in its entirety.The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating ...

Подробнее
13-02-2014 дата публикации

COMPOUNDS CONTAINING AN ALICYCLIE STRUCTURE AND ANTI-TUMOR APPLICATION

Номер: US20140045779A1
Автор: XU LIFENG
Принадлежит:

This invention relates with anti-tumor activities of new compounds containing an adamantyl group or analogs thereof. The invention also relates with the medication applications of anti-tumor and other diseases by this kind of compounds with the combination of S, P, T structures containing adamantyl group and the formation of stereoisomer, tautomers, prodrug, pharmaceutically acceptable salts, complex salts or solvates to their anticancer application and anticancer agents, which have the following general formula: 2. The compound according to the S formula of claim 1 , wherein:{'sub': 1', '2', '3', '4', '2', '1-10, 'The dotted lines are optionally substituted single bonds, optionally substituted double bond or a optionally substituted heterocyclic group containing carbon, oxygen, sulfur or nitrogen element; said X, X, X, Xare, independently at each occurrence, C═O, C═S, C═NH, C═Rb—Ra, CHOH, CHORb, CHRb or substituent, where Rb contains, independently at each occurrence, one or combination of C, N or P element; Ra is H, H, optionally substituted straight-alkyl, optionally substituted branched-alkyl, Coptionally substituted saturated alkyl, optionally substituted 1-4 double bond, optionally substituted 1-4 triple bond, optionally substituted unsaturated alkyl, optionally substituted saturated or unsaturated alicyclic, optionally substituted arylcyclic, optionally substituted aryl or optionally substituted heterocyclic, optionally substituted arylheterocyclic, fused heterocyclic group where contains hydroxyl, halogen, oxygen, nitrogen, sulfur, phosphorus element or selenium element;'}{'sub': 1', '2', '3', '4', '5', '6', '7', '8, 'said A, A, A, A, A, A, Aor Ais, independently at each occurrence, optionally substituted independently cyclic, alkyl, aryl, alicyclic, heterocyclic, aliphatic, aromatic heterocyclic, heterocyclic, glycosyl, multi-hydroxyl, amino acid, phosphate, acyloxyl, phosphoric, sulfonyloxyl, alkoxy, aryloxyl, heterocyclic oxyl, aryl cyclic, aliphatic ...

Подробнее
20-02-2014 дата публикации

STABLE CRYSTALLINE SALT OF (R)-3-FLUOROPHENYL-3,4,5-TRIFLUOROBENZYLCARBAMIC ACID 1-AZABICYCLO [2.2.2]OCT-3-YL ESTER

Номер: US20140051721A1
Принадлежит: LABORATORIOS SALVAT, S.A.

The present invention refers to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester and its use as medicament, in particular for the treatment of urinary incontinence or other diseases involving genitourinary disorders 2. The method of claim 1 , wherein the D-tartrate salt of compound I is a substantially anhydrous crystalline salt.3. The method of claim 1 , wherein the disease involving genitourinary disorders is urinary incontinence.4. The method of claim 1 , wherein the disease involving genitourinary disorders is overactive bladder.6. The method of claim 5 , wherein the D-tartrate salt of compound I is a substantially anhydrous crystalline salt.7. A method of claim 5 , wherein the disease or condition involving genitourinary disorders is urinary incontinence.8. A method of claim 5 , wherein the disease or condition involving genitourinary disorders is overactive bladder. The present invention relates to a stable crystalline salt of (R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester and to pharmaceutical formulations of this salt, in particular for medical use including treatment of urinary incontinence urge or other diseases involving genitourinary disorders.WO0200652 discloses compound I ((R)-3-fluorophenyl-3,4,5-trifluorobenzylcarbamic acid 1-azabicyclo [2.2.2]oct-3-yl ester) which has the following formula (I)Compound I is also disclosed in WO2004000840. On the other hand, compound I is exemplified as hydrochloride salt in WO2003053966 as an intermediate in the synthesis of other compounds. However, this acid addition salt known from the prior art had the disadvantage that its physicochemical stability was poor. Upon storage or formulation of said known salt, progressive decomposition and concomitantly an increase in the amount and number of impurities was observed. Obviously, this problem is further aggravated under demanding environmental conditions such ...

Подробнее
27-02-2014 дата публикации

3-(HETEROARYL-OXY)-2-ALKYL-1-AZA-BICYCLOALKYL DERIVATIVES AS ALPHA. 7-NACHR LIGANDS FOR THE TREATMENT OF CNS DISEASES

Номер: US20140057921A1
Принадлежит: NOVARTIS AG

The present invention relates to 1-aza-bicycloalkyl derivatives of formula (I) wherein the substituents are as defined in the specification, to processes for their production, their use as pharmaceuticals in the prevention and treatment of psychotic and neurodegenerative disorders. The claimed compounds act as nicotinic acetylcholine receptors (NACHR) ligands. 115-. (canceled)171. A method for treating or preventing a disease or condition in which α7 nAChR activation plays a role or is implicated , in a subject in need of such treatment , which comprises administering to such subject a therapeutically effective amount of a compound of claim in free base or pharmaceutically acceptable acid addition salt form.20. A method according to claim 17 , wherein the compound of formula I is selected from the group consisting of(2SR,3RS)-3-[5-(1H-Indol-5-yl)-pyridin-2-yloxy-]2-methyl-1-aza-bicyclo[2.2.2]octane;(+)-3-[5-(1H-Indol-5-yl)-pyridin-2-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;(−)-3-[5-(1H-Indol-5-yl)-pyridin-2-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;(2SR,3RS)-3-[6-(1H-Indol-5-yl)-pyridazin-3-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;(2S,3R)-3-[6-(1H-Indol-5-yl)-pyridazin-3-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;(2R,3S)-3-[6-(1H-Indol-5-yl)-pyridazin-3-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;(2SR,3RS)-3-[5-(1H-Indol-5-yl)-pyrimidin-2-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;{'b': '3-', '(2S,3R)--[5-(1H-Indol-5-yl)-pyrimidin-2-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane;'}{'b': '3-', '(2R,3S)--[5-(1H-Indol-5-yl)-pyrimidin-2-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane; and'}(2SR,3RS)-3-[6-(1H-Indol-5-yl)-pyridin-3-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane.21. A method according to claim 17 , wherein the compound of formula I is (2SR claim 17 ,3RS)-3-[6-(1H-Indol-5-yl)-pyridazin-3-yloxy]-2-methyl-1-aza-bicyclo[2.2.2]octane.22. A method according to claim 17 , wherein the compound of formula I is(2S,3R)-3-[6-(1H-Indol-5-yl)-pyridazin-3-yloxy]-2-methyl-1-aza- ...

Подробнее
20-03-2014 дата публикации

MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

Номер: US20140080863A1
Принадлежит: Glaxo Group Limited

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. 2. The compound according to wherein X is a pharmaceutically acceptable anion selected from the group consisting of chloride claim 1 , bromide claim 1 , iodide claim 1 , hydroxide claim 1 , sulfate claim 1 , nitrate claim 1 , phosphate claim 1 , acetate claim 1 , trifluoroacetate claim 1 , fumarate claim 1 , citrate claim 1 , tartrate claim 1 , oxalate claim 1 , succinate claim 1 , mandelate claim 1 , methanesulfonate claim 1 , and p-toluenesulfonate.3. The compound according to wherein M is O.4. The compound according to wherein n is 2.5. The compound according to wherein l is 2.6. The compound according to wherein V is CH.7. The compound according to wherein V is O.8. The compound according to wherein M is CH.9. The compound according to wherein l is 1.10. The compound according to wherein l is 2.15. The compound according to which is:4-[hydroxy(diphenyl)methyl]-1-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1-azoniabicyclo[2.2.2]octane bromide.16. A pharmaceutical composition comprising a compound according to claim 1 , and a pharmaceutically acceptable carrier thereof.17. A pharmaceutical composition comprising a compound according to claim 15 , and a pharmaceutically acceptable carrier thereof.18. A pharmaceutical composition according to in a form suitable for administration by oral or nasal inhalation.19. A pharmaceutical composition according to wherein the form is suitable for administration by inhalation via a medicament dispenser selected from a reservoir dry powder inhaler claim 18 , a multi-dose dry powder inhaler claim 18 , or a metered dose inhaler.20. A pharmaceutical composition according to which is a dry powder composition. This invention relates to novel quinuclidines derivatives, pharmaceutical compositions, and use thereof in treating muscarinic acetylcholine receptor mediated diseases of the respiratory tract.Acetylcholine released from cholinergic neurons in the ...

Подробнее
27-03-2014 дата публикации

Partially Saturated Tricyclic Compounds and Methods of Making and Using Same

Номер: US20140088078A1
Принадлежит: Zafgen, Inc.

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. 2. The tricyclic compound of claim 1 , wherein X′ is selected from the group consisting of: —O—* claim 1 , —N(R)—* claim 1 , —C(RR)—C(RR)—* claim 1 , —C(R)═C(R)—* claim 1 , —O—C(RR)—* claim 1 , —N(R)—C(RR)—* claim 1 , —O—C(O)—* claim 1 , —N(R)—C(O)—* claim 1 , —N═C(R)—* and —O—C(RR)—C(RR)—*;{'sup': '+', 'wherein the and * indicate the attachment points of X′ as indicated in Formula I.'}3. The tricyclic compound of claim 1 , wherein Xis selected from the group consisting of: —NH—* claim 1 , —O—CH—* claim 1 , —NH—CH—* claim 1 , —N═CH—* and —CH═CH—*;{'sup': '+', 'wherein the and * indicate the attachment points of X′ as indicated in Formula I.'}4. The tricyclic compound of claim 1 , wherein Xis selected from the group consisting of: —O—* claim 1 , —N(R)—* claim 1 , —C(RR)—C(RR)—* claim 1 , —O—C(RR)—* claim 1 , —N(R)—C(RR)—* claim 1 , —O—C(O)—* claim 1 , —N(R)—C(O)—* claim 1 , and —O—C(RR)—C(RR)—*; wherein the and * indicate the attachment points of Xas indicated in Formula II.5. The tricyclic compound of claim 1 , wherein Xis selected from the group consisting of: —O—CH—* and —NH—CH—*; wherein the and * indicate the attachment points of Xas indicated in Formula II.6. The tricyclic compound of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , Rand Rare independently selected for each occurrence from the group consisting of hydrogen and methyl.7. The tricyclic compound of claim 5 , wherein R claim 5 , R claim 5 , R claim 5 , Rand Rare hydrogen.8. The tricyclic compound of claim 1 , wherein R claim 1 , R claim 1 , Rand Rare independently selected for each occurrence from the group consisting of hydrogen claim 1 , fluorine claim 1 , cyano and Calkyl.9. The tricyclic compound of claim 7 , ...

Подробнее
27-03-2014 дата публикации

IMIDAZOPYRIDINE COMPOUNDS

Номер: US20140088080A1
Принадлежит: Astellas Pharma Inc.

[Problem] 2. The compound or a salt thereof according to claim 1 , wherein{'sup': '1', 'Ais cyclohexyl, or phenyl optionally substituted with one or more F atoms,'}{'sup': '1', 'Ris H,'}{'sup': 2', '0, 'Ris R,'}{'sup': '3', 'Ris H,'}{'sup': '5', 'Ris H,'}{'sup': 4', '2', '3, 'Ris —Y-Aor A,'}{'sub': '1-10', 'sup': '2', 'Y is Calkylene optionally substituted with at least one group selected from Group G,'}{'sup': '2', 'sub': '2', 'Group Gis —COH and —OH,'}{'sup': '2', 'sub': '2', 'Ais H, cycloalkyl, pyridyl, or phenyl optionally substituted with a group selected from the group consisting of lower alkyl and —COH,'}{'sup': 3', '1', '1, 'Ais cycloalkyl selected from the group consisting of cyclopentyl, indanyl, dihydrocyclopentathienyl, dihydrocyclopentafuranyl, and dihydrocyclopentapyrrolyl, the above cycloalkyl is optionally substituted with at least one group selected from Group G, or piperidyl or pyrrolidinyl each optionally substituted with at least one group selected from Group G, and'}{'sup': 1', '0', '0', '0, 'sub': 2', '2', '2', '2', '2', '3', '3, 'Group Gis R, halogen, —COH, —OH, —COR, —CN, —NO, phenyl, —SO—NH, —SOH, and —SOR.'}4. The compound or a salt thereof according to claim 3 , wherein Ais 2 claim 3 ,6-difluorophenyl claim 3 , Ris methyl claim 3 , Ris a group represented by the formula (A) or the formula (B) claim 3 , X is —HC═CH— claim 3 , n is 1 claim 3 , Ris F claim 3 , and Ris —COH.6. The compound or a salt thereof according to claim 3 , wherein Ris methyl and Ris a group represented by the formula (C) or (D).7. The compound or a salt thereof according to claim 3 , wherein Ais cyclohexyl or 2 claim 3 ,6-difluorophenyl claim 3 , Ris methyl claim 3 , Ris A claim 3 , Ais a group represented by the formula (A) or the formula (B) claim 3 , X is —HC═CH— claim 3 , n is 1 claim 3 , Ris each H claim 3 , Ris H claim 3 , and Ris —COH.8. The compound or a salt thereof according to claim 3 , wherein Ris methyl and Ris a group represented by the formula (E).9. The ...

Подробнее
02-01-2020 дата публикации

PHARMACEUTICAL COMPOSITION COMPRISING PYRIDONE DERIVATIVES

Номер: US20200000782A1
Принадлежит:

A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof. 17-. (canceled)9. The method of claim 8 , wherein B is NH.10. The method of claim 8 , wherein A is thiazolyl claim 8 , benzothiazolyl claim 8 , pyridyl claim 8 , isoxazolyl claim 8 , isoquinolinyl claim 8 , quinolyl claim 8 , benzothiadiazolyl claim 8 , thiadiazolyl claim 8 , pyrazolyl or pyrazinyl claim 8 , which is optionally substituted by at least one selected from the group consisting of halo claim 8 , chlorophenyl claim 8 , C-Calkyl claim 8 , C-Ccycloalkyl claim 8 , C-Caralkyl claim 8 , C-Calkoxy claim 8 , and C-Caryl.11. The method of claim 8 , wherein A is thiazolyl or benzothiazolyl optionally substituted by at least one selected from the group consisting of halo claim 8 , chlorophenyl claim 8 , C-Calkyl claim 8 , C-Ccycloalkyl claim 8 , C-Caralkyl claim 8 , C-Calkoxy claim 8 , and C-Caryl.12. The method of claim 8 , wherein A is C-Cheteroaryl substituted by at least one selected from the group consisting of chloro claim 8 , methyl claim 8 , ethyl claim 8 , propyl claim 8 , iso-propyl claim 8 , tert-butyl claim 8 , cyclopentyl claim 8 , phenyl claim 8 , chlorophenyl claim 8 , benzyl claim 8 , cyclohexyl and methoxy.13. The method of claim 8 , wherein A is selected from thiazolyl claim 8 , methylthiazolyl claim 8 , ethylthiazolyl claim 8 , propylthiazolyl claim 8 , iso-propylthiazolyl claim 8 , tert-butylthiazolyl claim 8 , cyclopentylthiazolyl claim 8 , cyclohexylthiazolyl claim 8 , phenylthiazolyl claim 8 , chlorophenylthiazolyl claim 8 , benzylthiazolyl claim 8 , chlorothiazolyl and dimethylthiazolyl.14. The method of claim 13 , wherein B is NH.15. The method of claim 8 , wherein the compound is selected from the group consisting of:N-(1-azabicyclo[ ...

Подробнее
07-01-2016 дата публикации

MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS

Номер: US20160002220A1
Принадлежит:

Methods of using Muscarinic Acetylcholine Receptor Antagonists are provided. 3. A compound according to selected from the group of:1-(2-{[(3-fluorophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide;4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide;1-(2-{[(4-bromophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide;1-(2-{[(4-chlorophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide;4-[bis(4-fluorophenyl)(hydroxy)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide;4-{hydroxy[bis(3-methylphenyl)]methyl}-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide;1-(2-{[(4-fluorophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide;4-[hydroxy(diphenyl)methyl]-1-{2-[(phenylcarbonyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide;1-{3-[(3-fluorophenyl)oxy]propyl}-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide;4-{hydroxy[bis(4-methylphenyl)]methyl}-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide;4-[hydroxy(diphenyl)methyl]-1-{3-[(methylsulfonyl)amino]propyl}-1-azoniabicyclo[2.2.2]octane bromide;4-[bis(3-fluorophenyl)(hydroxy)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane bromide;1-{3-[(3-chlorophenyl)oxy]propyl}-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide;4-[hydroxy(di-2-thienyl)methyl]-1-[3-(phenyloxy)propyl]-1-azoniabicyclo[2.2.2]octane bromide;4-[hydroxy(diphenyl)methyl]-1-[3-(phenyloxy)propyl]-1-azoniabicyclo[2.2.2]octane bromide;1-(2-{[(4-cyanophenyl)methyl]oxy}ethyl)-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide;1-{3-[(4-bromophenyl)oxy]propyl}-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide;4-[bis(4-fluorophenyl)(hydroxy)methyl]-1-[3-(phenyloxy)propyl]-1-azoniabicyclo[2.2.2]octane bromide;1-{3-[(4-fluorophenyl)oxy]propyl}-4-[ ...

Подробнее
02-01-2020 дата публикации

CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUANTERNARY AMMONIUM SALT STRUCTURE

Номер: US20200002329A1
Принадлежит: Beijing Showby Pharmaceutical Co., Ltd.

The invention provides a class of compounds represented by formula (I), having bifunctional active quaternary ammonium salt structure of a β-adrenoreceptor agonist and an M receptor antagonist, a pharmaceutically acceptable salt, solvate, and optical isomer thereof. A pharmaceutical composition comprising such a compound with quaternary ammonium salt structure, a method for preparing such a compound with quaternary ammonium salt structure and an intermediate thereof, and uses thereof in treating pulmonary disorders are also provided. The compounds of the invention have high selectivity to the M receptor subtype, and have less adverse reaction and lower toxic and side effects in the treatment of pulmonary diseases such as COPD and asthma. 2. The compound according to claim 1 , or the pharmaceutically acceptable salt claim 1 , solvate claim 1 , optical isomer thereof claim 1 , wherein L is an unsubstituted phenyl claim 1 , pyridyl claim 1 , furyl or thienyl.3. The compound according to claim 1 , or the pharmaceutically acceptable salt claim 1 , solvate claim 1 , optical isomer thereof claim 1 , wherein W is unsubstituted (3-7C)cycloalkyl.4. The compound according to claim 3 , or the pharmaceutically acceptable salt claim 3 , solvate claim 3 , optical isomer thereof claim 3 , wherein W is cyclobutyl claim 3 , cyclopentyl or cyclohexyl.5. The compound according to claim 1 , or the pharmaceutically acceptable salt claim 1 , solvate claim 1 , optical isomer thereof claim 1 , wherein Rand Rare each independently selected from (1-1° C.)alkylene claim 1 , -(1-4C)alkyleneoxy claim 1 , alkyleneamido; and Ais independently selected from (6-10° C.)arylene claim 1 , wherein the arylene may be unsubstituted or substituted with 1-2 substituents independently selected from halogen claim 1 , (1-6C)alkyl claim 1 , (1-6C)alkoxy claim 1 , carboxy claim 1 , nitro claim 1 , cyano claim 1 , amido claim 1 , and ester group.6. The compound according to claim 1 , or the pharmaceutically ...

Подробнее
04-01-2018 дата публикации

PARTIALLY SATURATED TRICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME

Номер: US20180002307A1
Принадлежит:

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. 144.-. (canceled)46. The tricyclic compound of claim 45 , wherein Ris selected from hydrogen or methyl.47. The tricyclic compound of claim 45 , wherein Ris selected from hydrogen or fluorine.48. The tricyclic compound of claim 45 , wherein Ris Calkenyl substituted by RRN—.49. The tricyclic compound of claim 45 , wherein Ris (Z)-3-(N claim 45 ,N-diethylamino)prop-1-enyl. This application is a continuation of U.S. patent application Ser. No. 15/014,524, filed Feb. 3, 2016; which is a continuation of U.S. patent application Ser. No. 14/116,023, filed Nov. 6, 2013; which is a national stage filing under U.S.C. §371 of PCT/US2012/036789, filed May 7, 2012; which claims priority to U.S. Provisional Patent Application 61/559,856, filed Nov. 15, 2011; and U.S. Provisional Patent Application 61/483,257, filed May 6, 2011; all of which are incorporated by reference in their entirety.Over 1.1 billion people worldwide are reported to be overweight. Obesity is estimated to affect over 90 million people in the United States alone. Twenty-five percent of the population in the United States over the age of twenty is considered clinically obese. While being overweight or obese presents problems (for example restriction of mobility, discomfort in tight spaces such as theater or airplane seats, social difficulties, etc.), these conditions, in particular clinical obesity, affect other aspects of health, i.e., diseases and other adverse health conditions associated with, exacerbated by, or precipitated by being overweight or obese. The estimated mortality from obesity-related conditions in the United States is over 300,000 annually (O'Brien et al. Amer J Surgery (2002) 184:4S-8S; and Hill et al. (1998) Science, ...

Подробнее
01-01-2015 дата публикации

PYRIDO[3,4-B] INDOLES AND METHODS OF USE

Номер: US20150005322A1
Принадлежит:

This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder. 17-. (canceled)9. (canceled) This application claims priority to U.S. Provisional Patent Application No. 61/245,140, filed Sep. 23, 2009, and U.S. Provisional Patent Application No. 61/245,259, filed Sep. 23, 2009, the disclosures of each of which are hereby incorporated herein by reference in their entireties.Not applicable.Neurotransmitters such as histamine, serotonin, dopamine and norepinephrine mediate a large number of processes in the central nervous system (CNS) as well as outside the CNS. Abnormal neurotransmitter levels are associated with a wide variety of diseases and conditions including, but not limited to, Alzheimer's disease, Parkinson's Disease, autism, Guillain-Barré syndrome, mild cognitive impairment, schizophrenia (such as cognitive impairment associated with schizophrenia (CIAS), positive symptoms, disorganized symptoms, and negative symptoms of schizophrenia), anxiety, multiple sclerosis, stroke, traumatic brain injury, spinal cord injury, diabetic neuropathy, fibromyalgia, bipolar disorders, psychosis, depression, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), depression and a variety of allergic diseases. Compounds that modulate these neurotransmitters may be useful therapeutics.Histamine receptors belong to the superfamily of G protein-coupled seven transmembrane proteins. G protein-coupled receptors constitute one of the major signal transduction systems in eukaryotic cells. Coding sequences for these receptors, in those regions believed to contribute to the agonist-antagonist binding ...

Подробнее
14-01-2016 дата публикации

QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY

Номер: US20160009706A1
Принадлежит:

Provided are substituted quinuclidine compounds, pharmaceutical compositions comprising such compounds, and methods of modulating α7 nicotinic acetylcholine receptors and treating neurological disorders using such compounds. 2. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris C-Calkyl or C-Ccycloalkyl claim 1 , wherein the C-Calkyl or C-Ccycloalkyl is unsubstituted or substituted with 1 to 5 halo substituents.3. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris unsubstituted C-Calkyl.4. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris —CH.5. The compound of claim 1 , or a salt thereof claim 1 , wherein R is C-Calkoxy claim 1 , which is unsubstituted or substituted with 1 to 5 halo substituents.6. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris —OCH.7. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris bromo.8. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris hydrogen.9. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris C-Calkyl or C-Ccycloalkyl.10. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris —CH.11. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris halo.12. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris fluoro or chloro.13. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris cyano.14. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris —OR claim 1 , and Ris hydrogen or unsubstituted C-Calkyl.15. The compound of claim 14 , or a salt thereof claim 14 , wherein Ris —CH.16. The compound of claim 1 , or a salt thereof claim 1 , wherein R is —OR claim 1 , and Ris C-Calkyl substituted with C-Calkoxy.17. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris hydrogen.18. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris C-Calkyl or C-Ccycloalkyl.19. The compound of claim 1 , or a salt thereof claim 1 , wherein Ris —CH.20. The compound of claim 1 , or ...

Подробнее
14-01-2016 дата публикации

CRYSTALLINE FORM OF (R)-7-CHLORO-N-(QUINUCLIDIN-3-YL)BENZO[B]THIOPHENE-2-CARBOXAMIDE HYDROCHLORIDE MONOHYDRATE

Номер: US20160009707A1
Принадлежит:

Crystalline Forms I and II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate and compositions, methods of manufacture and therapeutic uses thereof are described. 1. A crystalline Form II of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate , characterized by an x-ray powder diffraction pattern having peaks expressed as 2Θ at:i) one or both of 21.16 and 21.38±0.20 degrees when measured against an internal silicon standard; andii) at least four peaks selected from a group of peaks consisting of: 4.48, 9.00, 13.58, 15.62, 16.48, 19.02, 19.44, 22.46, and 25.00±0.20 degrees when measured against an internal silicon standard.2. The crystalline Form II of claim 1 , characterized by an x-ray powder diffraction pattern claim 1 , wherein at least six peaks are selected from the group of peaks.3. The crystalline Form II of claim 1 , characterized by an x-ray powder diffraction pattern claim 1 , wherein at least eight peaks are selected from the group of peaks.4. The crystalline Form II of claim 1 , characterized by an x-ray powder diffraction pattern claim 1 , wherein all of the peaks are selected from the group of peaks.5. A pharmaceutical composition comprising the crystalline Form II of .6. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is for the treatment of cognitive loss in a subject suffering from Alzheimer's disease.7. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is for the treatment of cognitive loss in a subject suffering from Schizophrenia.8. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is for the improvement of cognition in a subject suffering from Alzheimer's disease.9. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is for the improvement of cognition in a subject suffering from Schizophrenia.10. A pharmaceutical composition ...

Подробнее
11-01-2018 дата публикации

SALTS OF AZA-BICYCLIC DI-ARYL ETHERS AND METHODS TO MAKE THEM OR THEIR PRECURSORS

Номер: US20180009801A1
Принадлежит:

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments. 1. A salt of (R)-3-(6-(4-methylphenyI)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane wherein said salt is the fumarate , maleate , chloride , phosphate , succinate , or malonate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane.2. The salt according to claim 1 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form.3. The salt according to claim 2 , wherein the salt is characterized by an XRPD pattern substantially the same as the XRPD pattern shown in .4. The salt according to claim 1 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form claim 1 , wherein the mean particle size of the crystals is at least 15 μm.5. The salt according to claim 2 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form claim 2 , and wherein the salt is in substantially pure form.6. The salt according to claim 2 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form claim 2 , and wherein the salt has a purity greater than 90 weight %.7. A method for the prevention claim 1 , treatment claim 1 , and/or delay of progression of a disease or condition claim 1 , in which nAChR α7 activation plays a role or is implicated claim 1 , in a subject in need of such treatment claim 1 , which comprises administering to such subject a therapeutically effective amount of a salt as defined in .8. A method for the prevention claim 1 , treatment claim 1 , and/or delay of progression of psychiatric or neurodegenerative ...

Подробнее
10-01-2019 дата публикации

AMIDES OF ACETIC AND PROPIONIC ACIDS

Номер: US20190010150A1
Принадлежит: Bayer Intellectual Property GmbH

The invention relates to novel amides of acetic and propionic acids, methods for production and use thereof for the production of medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning ability and memory. 110-. (canceled)11: A method of improving perception , concentration , learning or memory , after a cognitive impairment in a patient in need thereof , comprising administering to the patient a compound selected from the group consisting of:2-(1-azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride;2-(1-azabicyclo[2.2.2]oct-3-yl)-N-(6-bromo-1-benzothien-2-yl)acetamide hydrochloride;2-(1-azabicyclo[2.2.2]oct-3-yl)-N-(7-quinolinyl)acetamide hydrochloride;2-(1-azabicyclo[2.2.2]oct-3-yl)-N-(2-naphthyl)acetamide hydrochloride; and2-(1-azabicyclo[2.2.2]oct-3-yl)-N-(8-nitro-2-naphthyl)acetamide hydrochloride.12: The method of claim 11 , wherein the cognitive impairment is mild cognitive impairment or Alzheimer's disease.13: The method of claim 11 , wherein the cognitive impairment is schizophrenia or schizophrenia with dementia.14: The method of claim 11 , wherein the compound is 2-(1-azabicyclo[2.2.2]oct-3-yl)-N-(7-bromo-1-benzothien-2-yl)acetamide hydrochloride.15: The method of claim 11 , wherein the compound is 2-(1-azabicyclo[2.2.2]oct-3-yl)-N-(6-bromo-1-benzothien-2-yl)acetamide hydrochloride.16: The method of claim 11 , wherein the compound is 2-(1-azabicyclo[2.2.2]oct-3-yl)-N-(7-quinolinyl)acetamide hydrochloride.17: The method of claim 11 , wherein the compound is 2-(1-azabicyclo[2.2.2]oct-3-yl)-N-(2-naphthyl)acetamide hydrochloride.18: The method of claim 11 , wherein the compound is 2-(1-azabicyclo[2.2.2]oct-3-yl)-N-(8-nitro-2-naphthyl)acetamide hydrochloride.20: The method of claim 19 , wherein the cognitive impairment is mild cognitive impairment or Alzheimer's disease.21: The method of claim 19 , wherein the cognitive impairment is schizophrenia or schizophrenia with ...

Подробнее
18-01-2018 дата публикации

Methods of Treating an Overweight or Obese Subject

Номер: US20180016249A1
Автор: Vath James E.
Принадлежит:

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAP-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject. 3. The method of claim 1 , wherein the subject has a Body Mass Index measurement selected from the group consisting of: at least about 25 kg/m claim 1 , at least about 30 kg/m claim 1 , and at least about 40 kg/m.412.-. (canceled)14. (canceled) This application is a continuation of U.S. Ser. No. 14/802,473, filed Jul. 17, 2015, which is a continuation of U.S. Ser. No. 14/616,002, filed Feb. 6, 2015, which is a continuation of U.S. Ser. No. 13/133,062, filed Sep. 22, 2011, (now abandoned) which is a national phase filing under 35 U.S.C. §371 of PCT/US2009/066809, filed Dec. 4, 2009, which claims priority to U.S. provisional applications U.S. Ser. No. 61/119,875 filed Dec. 4, 2008, U.S. Ser. No. 61/119,881 filed Dec. 4, 2008, U.S. Ser. No. 61/119,884 filed Dec. 4, 2008, U.S. Ser. No. 61/119,886 filed Dec. 4, 2008, U.S. Ser. No. 61/275,688 filed Aug. 3, 2009, and U.S. Ser. No. 61/260,194 filed Nov. 11, 2009, each application of which is hereby incorporated by reference in its entirety.Obesity is a complex medical disorder of appetite regulation and metabolism resulting in excessive accumulation of adipose tissue mass. Typically defined as a body mass index (BMI) of 30 kg/mor more, obesity is a world-wide public health concern that is associated with cardiovascular disease, diabetes, certain cancers, respiratory complications, osteoarthritis, gallbladder disease, decreased life expectancy, and work disability. The primary goals of obesity therapy are to reduce excess body weight, improve or prevent obesity- ...

Подробнее
26-01-2017 дата публикации

NORIBOGAINE SALT TABLETS

Номер: US20170022193A1
Принадлежит: DEMERX, INC.

Stable noribogaine salt ansolvates are useful for preparing pharmaceutical compositions and for alleviating nociceptive pain in a patient. Such ansolvates can be prepared by slurrying solvated forms, preferably MeOH solvated noribogaine hydrochloride in EtOH/water. 1. A stable pharmaceutically acceptable salt of noribogaine ansolvate.2. The stable salt of noribogaine ansolvate of claim 1 , wherein the salt is a hydrochloride salt.3. The salt of claim 2 , which is crystalline.4. The crystalline salt of claim 3 , characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 11.6° claim 3 , 12.1° claim 3 , 13.5° claim 3 , 13.9° claim 3 , 14.9° claim 3 , 15.7° claim 3 , 17.1 claim 3 , 17.9° claim 3 , 18.3° claim 3 , 19.8° claim 3 , 20.8° claim 3 , 21.0° claim 3 , 21.9° claim 3 , 22.8° claim 3 , 23.3° claim 3 , 24.9° claim 3 , 25.9° claim 3 , 26.4 claim 3 , 29.3° claim 3 , and 29.8°2θ (each ±0.2 °2θ).5. The crystalline salt of claim 3 , which shows substantially no thermal transitions under 300° C. in its differential scanning calorimetry thermogram.6. The crystalline salt of claim 3 , which shows substantially no weight loss at a temperature under 300° C. in its thermogravimetric analysis thermogram.7. The crystalline ansolvate salt of claim 3 , which has a density that is at least 3% and up to 20% greater than the density of a solvated crystalline hydrochloride salt of noribogaine.8. The crystalline ansolvate salt of claim 3 , which has a unit cell volume of less than about 1800 cubic angstrom claim 3 , or less than about 1750 cubic angstrom claim 3 , or less than 1700±2% cubic angstrom.9. A crystalline noribogaine hydrochloride solvate polymorph characterized by about 4% weight loss at temperatures under 125° C. in its differential scanning calorimetry thermogram.10. The crystalline solvate polymorph of characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 9.7 claim 9 , 10.2 claim 9 , 12.0 claim 9 , ...

Подробнее
26-01-2017 дата публикации

STABLE CRYSTALLINE NORIBOGAINE SALT ANSOLVATES

Номер: US20170022194A1
Принадлежит: DEMERX, INC.

Stable noribogaine salt ansolvates are useful for preparing pharmaceutical compositions and for alleviating nociceptive pain in a patient. Such ansolvates can be prepared by slurrying solvated forms, preferably MeOH solvated noribogaine hydrochloride in EtOH/water. 1. A stable pharmaceutically acceptable salt of noribogaine ansolvate.2. The stable salt of noribogaine ansolvate of claim 1 , wherein the salt is a hydrochloride salt.3. The salt of claim 2 , which is crystalline.4. The crystalline salt of claim 3 , characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 11.6° claim 3 , 12.1° claim 3 , 13.5° claim 3 , 13.9° claim 3 , 14.9° claim 3 , 15.7° claim 3 , 17.1 claim 3 , 17.9° claim 3 , 18.3° claim 3 , 19.8° claim 3 , 20.8° claim 3 , 21.0° claim 3 , 21.9° claim 3 , 22.8° claim 3 , 23.3° claim 3 , 24.9° claim 3 , 25.9° claim 3 , 26.4 claim 3 , 29.3° claim 3 , and 29.8° 2θ (each ±0.2° 2θ).5. The crystalline salt of claim 3 , which shows substantially no thermal transitions under 300° C. in its differential scanning calorimetry thermogram.6. The crystalline salt of claim 3 , which shows substantially no weight loss at a temperature under 300° C. in its thermogravimetric analysis thermogram.7. The crystalline ansolvate salt of claim 3 , which has a density that is at least 3% and up to 20% greater than the density of a solvated crystalline hydrochloride salt of noribogaine.8. The crystalline ansolvate salt of claim 3 , which has a unit cell volume of less than about 1800 cubic angstrom claim 3 , or less than about 1750 cubic angstrom claim 3 , or less than 1700±2% cubic angstrom.9. A crystalline noribogaine hydrochloride solvate polymorph characterized by about 4% weight loss at temperatures under 125° C. in its differential scanning calorimetry thermogram.10. The crystalline solvate polymorph of characterized by at least one X-ray powder diffraction peak (Cu Kα radiation) selected from 9.7 claim 9 , 10.2 claim 9 , 12.0 claim 9 , ...

Подробнее
17-04-2014 дата публикации

METHODS AND COMPOSITIONS FOR TREATING AMYLOID-RELATED DISEASES

Номер: US20140107027A1
Принадлежит: BHI LIMITED PARTNERSHIP

Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease. 1232-. (canceled)234. The compound of claim 233 , wherein Ris hydrogen.235. The compound of claim 233 , wherein Ris straight chain alkyl.236. The compound of claim 233 , wherein Ris t-butyl.237. The compound of claim 233 , wherein Ris carbocyclic.238. The compound of claim 233 , wherein Ris C-Cbicycloalkyl.239. The compound of claim 233 , wherein said bicyclic fused ring group is indolyl.240. The compound of claim 233 , wherein Lis CHCHor absent.251. A method of treating or preventing an amyloid-related disease in a subject comprising administering to a subject in need thereof a compound of in an amount effective to treat or prevent an amyloid related disease.252. The method according to claim 251 , wherein said amyloid-related disease is Alzheimer's disease claim 251 , cerebral amyloid angiopathy claim 251 , inclusion body myositis claim 251 , macular degeneration claim 251 , MCI claim 251 , or Down's syndrome.253. The method according to claim 251 , wherein amyloid fibril formation or deposition claim 251 , neurodegeneration claim 251 , microglial inflammatory response claim 251 , or cellular toxicity is reduced or inhibited upon administration of said compound.254. The method according to claim 251 , wherein said amyloid-related disease is diabetes claim 251 , AA amyloidosis claim 251 , AL amyloidosis claim 251 , or hemodialysis related amyloidosis (βM).255. The method of claim 251 , wherein said subject has Alzheimer's disease claim 251 , Mild Cognitive Impairment claim 251 , or cerebral amyloid angiopathy claim 251 , and stabilization of cognitive function claim 251 , prevention of a further decrease in cognitive function claim 251 , or prevention claim 251 , slowing claim 251 , or stopping of disease progression occurs in said patient upon administration.256. A method for inhibiting amyloid deposition in a subject comprising administering ...

Подробнее
10-02-2022 дата публикации

QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION

Номер: US20220041641A1
Принадлежит:

Provided are compounds that can inhibit pathogenic, bacterial metabolite production and conjugates of the same. Also provided are pharmaceutical compositions comprising the same and methods of using the same. 5. The compound of claim 4 , wherein Ris Calkyl substituted with —O-(acylated sugar) and is optionally further substituted with oxo.6. The compound of or claim 4 , wherein Ris methyl.7. The compound of any one of claim 4 , claim 4 , and claim 4 , wherein Ris Calkyl.8. The compound of any one of - claim 4 , wherein Ris propargyl.9. The compound of claim 4 , wherein{'sup': '1', 'sub': '2-6', 'Ris Calkyl substituted with —O-(acylated sugar) and is optionally further substituted with oxo;'}{'sup': '2', 'Ris methyl;'}{'sup': '3', 'sub': '1-6', 'Ris Calkyl; and'}{'sup': '4', 'Ris propargyl.'}10. The compound of claim 4 , wherein{'sup': '1', 'sub': '2-6', 'Ris Calkyl substituted with isosorbide and is optionally further substituted with oxo and/or methene;'}{'sup': '2', 'Ris methyl;'}{'sup': '3', 'sub': '1-6', 'Ris Calkyl; and'}{'sup': '4', 'Ris propargyl.'}13. The compound of claim 4 , wherein{'sup': '1', 'sub': 3-4', '1-2, 'Ris Ccycloalkyl Calkyl;'}{'sup': '2', 'sub': '2-6', 'Ris Calkyl optionally substituted with one or two hydroxyl, oxo, and —O-(acylated sugar);'}{'sup': 1', '2', 's', 's, 'sub': 2', 'n, 'or Rand R, together with the nitrogen atom to which both are attached, combine to form a 4- or 5-membered heterocyclic ring optionally substituted with ethynyl or —(CH)—ORor an acylated sugar, wherein n is 0 or 1, Ris hydrogen or an acylated sugar;'}{'sup': '3', 'sub': '1-6', 'Ris Calkyl optionally substituted with a halogen or hydroxyl; and'}{'sup': '4', 'sub': '1-6', 'Ris Calkyl or propargyl.'}14. The compound of claim 13 , wherein Ris Ccycloalkyl Calkyl.15. The compound of or claim 13 , wherein Ris Calkyl optionally substituted with one or two hydroxyl groups.16. The compound of claim 13 , wherein Rand R claim 13 , together with the nitrogen atom to which both ...

Подробнее
28-01-2021 дата публикации

PROCESS FOR THE PREPARATION OF ISOXAZOLINE COMPOUNDS

Номер: US20210022344A1
Автор: Yang ChunHua

This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine-based chiral phase transfer catalyst. The invention also relates to novel quinine-based phase transfer catalysts and to a toluene solvent form of the isoxazoline compound of the invention. 2. The process of claim 1 , wherein the compound of formula (I) enriched in one enantiomer is isolated by crystallizing the compound from an aromatic solvent or a mixture of solvents comprising an aromatic solvent.3. The process of claim 2 , wherein the aromatic solvent is selected from the group consisting of toluene claim 2 , ethylbenzene claim 2 , xylenes claim 2 , chlorobenzene claim 2 , o-dichlorobenzene claim 2 , fluorobenzene claim 2 , anisole and mesitylene claim 2 , or a combination thereof.4. The process of claim 3 , wherein the aromatic solvent is toluene.5. The process of claim 1 , wherein prior to isolating the compound of formula (I) enriched in an enantiomer claim 1 , the process further comprises crystallizing racemic compound of formula (I) and removing the solid.7. The process according to claim 1 , wherein Q is —C(O)NHCHC(O)NHCHCF claim 1 , —C(O)CHS(O)CH claim 1 , —C(O)NHCHCHSCHor (—CH—)(—CH—)N(CO)CHS(O)CH.8. The process according to claim 1 , wherein X in the chiral phase transfer catalyst of formula (IIIa) or (IIIb) is a halogen counter ion.9. The process according to claim 7 , wherein X is a chloride counter ion.10. The process according to claim 1 , wherein R in the chiral phase transfer catalyst of formula (IIIa) or (IIIb) is a phenyl group that is substituted by 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 or 5 aralkoxy groups.11. The process according to claim 10 , wherein the aralkoxy group is a benzyloxy group.12. The process according to claim 10 , wherein R is substituted with 3 aralkoxy groups.13. The process according to claim 12 , wherein R is 3 claim 12 ,4 claim 12 ,5-tris(benzyloxy)phenyl.1471-. (canceled)72. The process ...

Подробнее
29-01-2015 дата публикации

Substituted Pyrazolo [1,5-A] Pyrimidine Compounds as TRK Kinase Inhibitors

Номер: US20150031667A1
Принадлежит:

Compounds of Formula I: 2. The method of claim 1 , wherein:{'sup': '1', 'Ris H or -(1-6C alkyl);'}{'sup': 2', '1', '1', '2', '2', '1, 'sub': 2', '2', '2', '2', '2, 'Ris H, -(1-6C)alkyl, -(1-6C)fluoroalkyl, -(1-6C)hydroxyalkyl, -(2-6C)dihydroxyalkyl, -(1-6C alkyl)CN, -(1-6C alkyl)SONH, -(1-6C alkyl)NHSO(1-3C alkyl), -(1-6C alkyl)NH, -(1-6C alkyl)NH(1-4C alkyl), -(1-6C alkyl)N(1-4C alkyl), -(1-6C alkyl)hetCyc, -(1-6C alkyl)hetAr, hetAr, hetCyc, —O(1-6C alkyl), —O(3-6C cycloalkyl), Cyc, or a bridged 7-membered cycloalkyl ring,'}{'sup': 1', '2, 'sub': 2', '2, 'or NRRforms a 4-6 membered azacyclic ring optionally substituted with one or more substituents independently selected from -(1-6C)alkyl, —OH, —COH and -(1-3C alkyl)COH;'}{'sup': 1', '1, 'hetCycis a 5-6 membered heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCycis optionally substituted with oxo;'}{'sup': 2', '2, 'sub': 2', '2', '2, 'hetCycis a 6 membered carbon-linked heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O, wherein hetCycis optionally substituted with F, SONH, or SO(1-3C alkyl);'}{'sup': '1', 'hetAris a 5-membered heteroaryl ring having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with -(1-4C)alkyl;'}{'sup': '2', 'hetAris a 5-6 membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from -(1-4C)alkyl;'}{'sup': '1', 'sub': '2', 'Cycis 3-6 membered cycloalkyl ring which is optionally substituted with one or more substituents independently selected from -(1-4C alkyl), —OH, —OMe, —COH and -(1-4C alkyl)OH;'}{'sub': 3', '2, 'sup': '3', 'Y is (i) phenyl optionally substituted with one or more substituents independently selected from halogen, -(1-4C)alkoxy, —CF—CHF, —O(1-4C alkyl)hetCycand —O(1-4C alkyl)O(1-3C alkyl), or (ii) a 5-6 membered heteroaryl ring having a ring heteroatom selected from N and S, wherein said ...

Подробнее
29-01-2015 дата публикации

DIAZABICYCLO[3.3.1]NONANES, METHODS OF SYNTHESIS, AND USES THEREOF

Номер: US20150031675A1
Принадлежит:

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS). 2. (canceled)3. A method for treatment of central nervous system disorders and dysfunctions claim 1 , comprising administering to a mammal in need of such treatment claim 1 , a therapeutically effective amount of the compound according to .4. The method of claim 3 , wherein the disorder is selected from the group consisting of age-associated memory impairment claim 3 , mild cognitive impairment claim 3 , pre-senile dementia claim 3 , early onset Alzheimer's disease claim 3 , senile dementia claim 3 , dementia of the Alzheimer's type claim 3 , Lewy body dementia claim 3 , vascular dementia claim 3 , Alzheimer's disease claim 3 , stroke claim 3 , AIDS dementia complex claim 3 , attention deficit disorder claim 3 , attention deficit hyperactivity disorder claim 3 , dyslexia claim 3 , schizophrenia claim 3 , schizophreniform disorder claim 3 , schizoaffective disorder claim 3 , cognitive deficits in schizophrenia claim 3 , and cognitive dysfunction in schizophrenia.5. The method of claim 4 , wherein the disorder is selected from the group consisting of mild to moderate dementia of the Alzheimer's type claim 4 , attention deficit disorder claim 4 , attention deficit hyperactivity disorder claim 4 , mild cognitive impairment claim 4 , age-associated memory impairment claim 4 , cognitive deficits in schizophrenia claim 4 , and cognitive dysfunction in schizophrenia.6. A pharmaceutical composition comprising a compound according to claim 1 , and one or more pharmaceutically acceptable carrier.7. (canceled)8. A method of treating inflammation claim 1 , the inflammatory ...

Подробнее
02-02-2017 дата публикации

NOVEL SUBSTITUTED IMIDAZOQUINOLINES

Номер: US20170029422A1
Принадлежит: 4SC AG

Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents. 2. The compound of formula I according to claim 1 , wherein Ris selected from the group consisting of alkyl claim 1 , alkenyl claim 1 , aryl claim 1 , heteroaryl claim 1 , cycloalkyl claim 1 , and heterocyclyl claim 1 ,{'sub': '3', 'each of which may be unsubstituted or substituted by one or more substituents selected from group consisting of: —H, alkyl, alkenyl, alkoxy, halogen, —OH, —N, trifluromethyl, -alkyl-aryl, —O-alkyl-aryl, —CO-aryl, aryl, heterocyclyl, heteroaryl, —CO-heteroaryl, —CO-substituted aryl, —CO-substituted heteroaryl, —CO—O-alkyl, —CO—N-alkyl, —CO—N-aryl.'}3. The compound of formula I according to claim 1 , wherein Ris selected from the group consisting of alkyl claim 1 , alkynyl claim 1 , aryl claim 1 , alkoxy claim 1 , heterocyclyl and heteroaryl claim 1 , each of which may be optionally substituted by one or more substituents which are selected from the group consisting of: —H claim 1 , —OH claim 1 , halogen claim 1 , —CO—N(R) claim 1 , —N(R) claim 1 , —CO—Calkyl claim 1 , —CO—O—Calkyl claim 1 , —N claim 1 , optionally substituted aryl claim 1 , heterocyclyl and —CO-aryl claim 1 ,{'sub': 4', '1-10', '1-10, 'wherein each Ris independently selected from the group consisting of: —H, —Calkyl, —Calkyl-aryl, or aryl.'}4. The compound of formula I according to claim 1 , wherein Ris substituted by one or more substituents which are selected from the group consisting of: —H claim 1 , —OH claim 1 , halogen claim 1 , —CN claim 1 , —NO claim 1 , —COOH claim 1 , —SH claim 1 , —CO—Calkyl claim 1 , —CO—O—Calkyl claim 1 , —N claim 1 , optionally substituted aryl claim 1 , heterocyclyl claim 1 , —CO-aryl and —CO-heterocyclyl.5. The compound of formula I according to claim 1 , wherein Ris hydrogen.6. The compounds of formula I according to ...

Подробнее
29-01-2015 дата публикации

BIS-QUARTERNARY CINCHONA ALKALOID SALTS AS ASYMMETRIC PHASE TRANSFER CATALYSTS

Номер: US20150031891A1
Принадлежит: Merck Sharp & Dohme Corp.

The invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. The present invention is directed to novel bis-quarternary cinchona alkaloid salts and the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis. On certain substrates and under specific reaction conditions, the inventors have discovered that the use of bis-quarternary cinchona alkaloid salts in asymmetric phase transfer catalysis surprisingly provides for a more active and efficient process as compared to mono-quarternary catalysts. 2. The process of wherein said bis-quaternary cinchona alkaloid salt is used as a phase transfer catalyst in one of the following asymmetric reactions:(1) alkylation with an electrophilic alkylating agent,(2) Michael addition with an electron deficient olefin,(3) aldol reaction with an aldehyde,(4) Mannich reaction with a α-imino ester,(5) Darzens reaction with an aldehyde,(6) Neber rearrangement of an oxime into an α-aminoketone,(7) epoxidation of an electron deficient olefin,(8) aziridination of an electron deficient olefin,(9) dihydroxylation of an electron deficient olefins,(10) fluorination of a carbonyl substrate, and(11) sulfenylation of a β-keto sulfoxide.4. The process according to wherein:{'sup': A', 'B, 'claim-text': (i) hydrogen,', '(ii) halogen,', {'sup': '7', '(iii) OR,'}, {'sup': '7', 'sub': '2', '(iv) N(R),'}, '(v) CN,', {'sub': 1-8', '2-8', '3', '2', '2', '2', '2', '2', '2', '2, 'sup': 7', '7', '7', '7', '7', '7', '7', '8', '7', '8, '(vi) Calkyl or Calkenyl, either of which optionally bears up to 3 substituents independently selected from halogen, OH, CN, CF, OR, SR8, SOR8, SON(R), COR, COR, CON(R), N(R), NRCORand NRSOR; and'}, {'sub': 3-10', '3-10', '1-4', '1-4', '1-4', '3', '2', '2', '2', '2', '2', '2', '2, 'sup': 8', '7', '8', '8', '7', '7', '7', '7', '7', '7', '8', '7', '8, '(vii) Ccycloalkyl, CcycloalkylCalkyl, Het, ...

Подробнее
31-01-2019 дата публикации

METHOD OF PREPARING GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Номер: US20190031652A1
Принадлежит: Genzyme Corporation

The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. 122.-. (canceled)24. (canceled) The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Glucosylceramide synthase (GCS) is a pivotal enzyme which catalyzes the initial glycosylation step in the biosynthesis of glucosylceramide-base glycosphingolipids (GSLs) namely via the pivotal transfer of glucose from UDP-glucose (UDP-Glc) to ceramide to form glucosylceramide. GCS is a transmembrane, type III integral protein localized in the cis/medial Golgi. Glycosphingolipids (GSLs) are believed to be integral for the dynamics of many cell membrane events, including cellular interactions, signaling and trafficking. Synthesis of GSL structures has been shown (see, Yamashita et al., Proc. Natl. Acad. Sci. USA 1999, 96(16), 9142-9147) to be essential for embryonic development and for the differentiation of some tissues. Ceramide plays a central role in sphingolipid metabolism and downregulation of GCS activity has been shown to have marked effects on the sphingolipid pattern with diminished expression of glycosphingolipids. Sphingolipids (SLs) have a biomodulatory role in physiological as well as pathological cardiovascular conditions. In particular, sphingolipids and their regulating enzymes appear to play a role in adaptive responses to chronic hypoxia in the neonatal rat heart (see, El Alwanit et al., Prostaglandins & Other Lipid Mediators 2005, 78(1-4), 249-263).GCS inhibitors have been proposed for the treatment of a variety of diseases (see for example, WO2005068426). Such treatments include ...

Подробнее
11-02-2016 дата публикации

METHOD OF PREPARING GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Номер: US20160039806A1
Принадлежит:

The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. 4. A method according to , or , wherein n is 1; t is 0; y is 1 and z is 1.5. A method according to claim 4 , wherein Xis CRR.6. A method according to claim 5 , wherein Rand Rare each methyl.7. A method according to claim 6 , wherein Ais (C-C)heteroaryl.8. A method according to claim 7 , wherein Ais thiophene claim 7 , thiazole claim 7 , isothiazole claim 7 , furane claim 7 , oxazole claim 7 , isoxazole claim 7 , pyrrole claim 7 , imidazole claim 7 , pyrazole claim 7 , triazole claim 7 , pyridine claim 7 , pymiridine claim 7 , pyridazine claim 7 , indole claim 7 , benzotiazole claim 7 , benzoisoxazole claim 7 , benzopyrazole claim 7 , benzoimidazole claim 7 , benzofuran claim 7 , benzooxazole or benzoisoxazole.9. A method according to claim 8 , wherein Ais thiazole.10. A method according to claim 9 , wherein Ris H.11. A method according to claim 10 , wherein Xis a direct bond.12. A method according to claim 11 , wherein Ais (C-C)aryl.13. A method according to claim 12 , wherein Ais phenyl.14. A method according to claim 13 , wherein the phenyl group is substituted by halo.15. A method according to claim 14 , wherein the halo group is fluoro.16. A method according to claim 15 , wherein Ris hydrogen. The invention relates to a method of preparing inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.Glucosylceramide synthase (GCS) is a pivotal enzyme which catalyzes the initial glycosylation step in the biosynthesis of glucosylceramide-base glycosphingolipids (GSLs) namely via the pivotal transfer of glucose from UDP-glucose (UDP-Glc) to ...

Подробнее
07-02-2019 дата публикации

HETEROARYL CARBOXAMIDES

Номер: US20190040057A1
Принадлежит:

The invention relates to novel heteroaryl carboxamides, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory. 19-. (canceled)10: A method of treating a cognitive impairment in a patient in need thereof , comprising administering to the patient a compound selected from the group consisting of:N-(1-Azabicyclo[2.2.2]oct-3-yl)-6-quinolinecarboxamide hydrochloride;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-phenazinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-7-quinolinecarboxamide hydrochloride;N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-6-quinolinecarboxamide hydrochloride;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-7-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-6-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-methyl-7-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-methyl-6-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-4-methyl-6-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl]-2-propyl-6-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-4-methyl-6-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-propyl-7-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-ethyl-4-methyl-7-quinolinecarboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-4-(tetrahydro-2H-pyran-2-yl)-6-quinoline-carboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-4-(tetrahydro-2H-pyran-2-yl)-7-quinoline-carboxamide;N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-phenyl-6-quinolinecarboxamide; andN-(1-Azabicyclo[2.2.2]oct-3-yl)-2-phenyl-7-quinolinecarboxamide;or a salt thereof.11: The method of claim 10 , wherein the cognitive impairment is Alzheimer's disease.12: The method of claim 10 , wherein the cognitive impairment is schizophrenia.13: The method of claim 10 , wherein the method improves perception claim 10 , concentration claim 10 , learning claim 10 , or memory.14: A method of treating a cognitive impairment in a patient in need thereof claim 10 , ...

Подробнее
12-02-2015 дата публикации

(2S,3R)-N-2-3-PYRIDINYLMETHYL-1-AZABICYCLO 2.2.2 OCT-3-YL BENZOFURAN-2-CARBOXAMIDE, NOVEL SALT FORMS, AND METHODS OF USE THEREOF

Номер: US20150045386A1
Принадлежит:

The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central and autonomic nervous systems. 1. A method for treating a neurodegenerative disorder comprising administering a compound (2S ,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide or a pharmaceutically acceptable salt thereof , substantially free of (2S ,3S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide , (2R ,3S)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide , (2R ,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide , and pharmaceutically acceptable salts thereof.2. The method of claim 1 , wherein the treatment is for dementia.3. The method of claim 1 , wherein the treatment is for ataxia. The present invention is a continuation of U.S. patent application Ser. No. 13/947,157 filed Jul. 22, 2013, which is a continuation of U.S. patent application Ser. No. 13/116,080, filed May 26, 2011, now U.S. Pat. No. 8,541,446, issued Sep. 24, 2013, which is a continuation of U.S. patent application Ser. No. 12/184,312, filed Aug. 1, 2008, now U.S. Pat. No. 7,981,906 issued Jul. 19, 2011, which claims benefit to U.S. Provisional Application Nos. 60/971,654, filed Sep. 12, 2007, 60/953,610, filed Aug. 2, 2007, 60/953,613, filed Aug. 2, 2007, and 60/953,614 filed Aug. 2, 2007, each of which is incorporated herein by reference in its entirety.The present invention relates to (2S,3R)—N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms thereof, methods for its preparation, novel intermediates, and methods for treating a wide variety of conditions and disorders, including those associated ...

Подробнее
18-02-2021 дата публикации

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

Номер: US20210047333A1
Принадлежит:

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 1188-. (canceled)190. The process of claim 189 , wherein the suitable conditions to form an amine comprise reacting the compound of formula 27 under Buchwald-Hartwig amination conditions.192. The process of claim 191 , wherein suitable halogen exchange conditions comprise reacting the compound of formula 18 with potassium fluoride in the presence of an aprotic solvent and a phase transfer catalyst.193. The process of claim 192 , wherein the aprotic solvent is independently selected from DMSO claim 192 , DMF claim 192 , and sulfolane.194. The process of claim 192 , wherein the phase transfer catalyst is MeNCl.195. The process of claim 191 , wherein suitable displacement conditions comprise reacting the compound of formula 32 with a compound of formula 22 in the presence of a base.196. The process of claim 195 , wherein the base is an aliphatic amine.197. The process of claim 196 , wherein the aliphatic amine is DIPEA.199. The process of claim 198 , wherein suitable halogenation conditions comprise 1) reacting the compound of formula 31 with a base to generate an anion; and 2) reacting the anion with a chlorinating agent.200. The process of claim 199 , wherein the base is LDA.201. The process of claim 199 , wherein the chlorinating agent is 1 claim 199 ,1 claim 199 ,1 claim ...

Подробнее
16-02-2017 дата публикации

Geminal Substituted Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors

Номер: US20170044155A1
Принадлежит:

The present invention relates to novel geminal substituted aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of α7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom. 2. The compound of claim 1 , wherein Rindependently represents —H claim 1 , -D claim 1 , or halogen radical.35-. (canceled)6. The compound of claim 1 , wherein Rindependently represents —H claim 1 , -D claim 1 , or halogen radical.713-. (canceled)14. The compound of claim 1 , wherein Rindependently represents —F claim 1 , —Cl claim 1 , —Br claim 1 , —CN claim 1 , —CH claim 1 , —CHCH claim 1 , cyclopropyl radical claim 1 , —CHF claim 1 , —CHF claim 1 , —CF claim 1 , —CHCF claim 1 , —OCH claim 1 , —OCHCH claim 1 , —OCH(CH) claim 1 , —O-cyclopropyl claim 1 , or —OCF.15. (canceled)16. The compound of claim 1 , wherein Rindependently represents —F claim 1 , —Cl claim 1 , —CH claim 1 , or —OCH.1718-. (canceled)19. The compound of claim 1 , wherein Rindependently represents —H claim 1 , -D claim 1 , —F claim 1 , —Cl claim 1 , —CN claim 1 , —CH claim 1 , —CH(CH) claim 1 , cyclopropyl radical claim 1 , cyclobutyl radical claim 1 , —CHF claim 1 , —CHF claim 1 , —CF claim 1 , —CHCF claim 1 , —OCH claim 1 , —OCHCH claim 1 , —OCH(CH) claim 1 , —O-cyclopropyl claim 1 , —OCF claim 1 , or —OCHCF.20. (canceled)21. The compound of claim 1 , wherein Rindependently represents —H claim 1 , -D claim 1 , —F claim 1 , —Cl claim 1 , —CH claim 1 , or —OCH.22. The compound of claim 1 , wherein Rand Rindependently represent —H or -D.2326-. (canceled)27. The compound of claim 1 , wherein ...

Подробнее
13-02-2020 дата публикации

CINCHONINE-DERIVED CATALYSTS AND METHODS OF USING SAME

Номер: US20200048243A1
Автор: Deng Li, WU YONGWEI
Принадлежит: BRANDEIS UNIVERSITY

The present invention includes certain conchinine-derived phase-transfer catalysts of formula (I), compositions comprising the same, and methods of promoting asymmetric addition reactions using the same. 2. The compound of claim 1 , wherein Ris selected from the group consisting of alkyl claim 1 , alkoxy and aryl.3. The compound of claim 1 , wherein Rand Rare independently selected from the group consisting of alkyl claim 1 , alkoxy and aryl.4. The compound of claim 1 , wherein Ris aryl.5. The compound of claim 1 , wherein at least one selected from the group consisting of Rand Ris aryl claim 1 , which is independently optionally substituted with at least one sub stituent selected from alkyl claim 1 , alkoxy claim 1 , —S(alkyl) claim 1 , and —OSiR.6. The compound of claim 5 , wherein Rand Rare both independently aryl claim 5 , each of which is independently optionally substituted with at least one substituent selected from alkyl claim 5 , alkoxy claim 5 , —S(alkyl) claim 5 , and —OSiR.7. The compound of claim 1 , wherein Ris selected from the group consisting of alkyl claim 1 , alkoxy claim 1 , aryloxy claim 1 , —S(alkyl) claim 1 , —S(aryl) claim 1 , —OSiRand —NR.8. The compound of claim 7 , wherein Ris selected from the group consisting of alkoxy and —OSiR.9. The compound of claim 7 , wherein each occurrence of R is independently alkyl.10. The compound of claim 1 , wherein Ris selected from the group consisting of 3 claim 1 ,5-dimethoxyphenyl claim 1 , 3-phenyl-phenyl claim 1 , 3 claim 1 ,5-diphenyl-phenyl claim 1 , 3 claim 1 ,5-(4-methoxyphenyl)-phenyl claim 1 , 3 claim 1 ,5-diphenyl-4-methoxy-phenyl and 3 claim 1 ,5-diphenyl-4-(t-butyldimetylsiloxy)-phenyl.11. The compound of claim 1 , wherein Ris selected from the group consisting of unsubstituted alkyl claim 1 , unsubstituted alkenyl and unsubstituted alkynyl.12. The compound of claim 11 , wherein Ris selected from the group consisting of unsubstituted alkyl and unsubstituted alkenyl.13. The compound of claim ...

Подробнее
13-02-2020 дата публикации

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Номер: US20200048266A1
Принадлежит:

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer. 2271-. (canceled)273. A method for treating a disease or disorder mediated by glucosylceramide synthase (GCS) or a disease or disorder in which GCS is implicated in a subject in need of such treatment claim 1 , the method comprising the step of administering to the subject an effective amount of a compound according to .275. The method according to claim 274 , wherein Rand Rare each methyl.276. The method according to claim 274 , wherein Ris H.277. The method according to claim 274 , Xis a direct bond278. The method according to claim 274 , Xis a CRR.279. The method according to claim 278 , wherein Rand Rare each methyl.280. The method according to claim 274 , wherein Ais (C-C)aryl.281. The method according to claim 274 , wherein Ais (C-C)heteroaryl.282. The method according to claim 281 , wherein Ais pyridine.283. The method according to claim 274 , wherein Ais (C-C)heterocycloalkyl.284. The method according to claim 283 , wherein Ais pyrrolidinyl claim 283 , tetrahydrofuranyl claim 283 , dihydrofuranyl claim 283 , tetrahydropyranyl claim 283 , pyranyl claim 283 , thiopyranyl claim 283 , aziridinyl claim 283 , azetidinyl claim 283 , oxiranyl claim 283 , methylenedioxyl claim 283 , chromenyl claim 283 , barbituryl claim 283 , isoxazolidinyl claim 283 , 1 claim 283 ,3-oxazolidin-3-yl claim 283 , isothiazolidinyl claim 283 , 1 claim 283 ,3-thiazolidin-3-yl claim 283 , 1 claim 283 ,2-pyrazolidin-2-yl claim 283 , 1 claim 283 ,3-pyrazolidin-1-yl claim 283 , piperidinyl claim 283 , thiomorpholinyl claim 283 , 1 claim 283 ,2-tetrahydrothiazin-2-yl claim 283 , 1 claim 283 ,3-tetrahydrothiazin-3-yl claim 283 , tetrahydrothiadiazinyl claim 283 , morpholinyl claim 283 , 1 claim 283 ,2-tetrahydrodiazin-2-yl claim 283 , 1 claim 283 ...

Подробнее
22-02-2018 дата публикации

QUINUCLIDINE DERIVATIVE

Номер: US20180051018A1
Принадлежит: LTT Bio-Pharma Co., Ltd.

Provided is a novel therapeutic agent for chronic obstructive pulmonary disease. 2: The quinuclidine derivative according to claim 1 , wherein:m is an integer of 2 to 5;l is a number of 0 or 1; andn is a number of 0 or 1.3: The quinuclidine derivative according to claim 1 , wherein n is 0.4: The quinuclidine derivative according to claim 1 , wherein:m is 3; andl is 0.5: The quinuclidine derivative according to claim 1 , wherein the quinuclidine derivative is an (R) isomer.6: A medicament claim 1 , comprising the quinuclidine derivative according to as an active ingredient.7: The medicament according to claim 6 , wherein the medicament is a therapeutic agent for chronic obstructive pulmonary disease.8: A pharmaceutical composition claim 1 , comprising the quinuclidine derivative according to claim 1 , and a pharmaceutically acceptable carrier.911-. (canceled)12: A method for treating chronic obstructive pulmonary disease claim 1 , the method comprising administering an effective amount of the quinuclidine derivative according to . The present invention relates to a quinuclidine derivative, and to a medicament containing the quinuclidine derivative.Chronic obstructive pulmonary disease (COPD) is a generic term for diseases that have been conventionally called chronic bronchitis or emphysema. COPD is a chronic disease of the lungs, which is caused by long-term inhalation exposure of harmful substances mainly containing tobacco smoke, and is said to be a lifestyle-related disease that occurs in middle-aged or older people against the background of smoking habit.In the drug therapy for COPD, a bronchodilator (an anticholinergic drug, a β-agonist, or a theophylline drug) is mainly used, and an inhaled anticholinergic drug or an inhaled β-agonist that mainly dilates the bronchi for a long time is used. In addition, an inhaled corticosteroid is used in severe cases.In recent years, as a drug effective for the treatment of COPD, for example, a quinuclidine derivative as a ...

Подробнее
13-02-2020 дата публикации

RESIST COMPOSITION AND PATTERNING PROCESS

Номер: US20200050105A1
Принадлежит: SHIN-ETSU CHEMICAL CO., LTD.

A resist composition comprising a base polymer and a quencher in the form of an amine compound having an iodized aromatic ring bonded to the nitrogen atom via a divalent hydrocarbon group offers a high sensitivity and minimal LWR or improved CDU, independent of whether it is of positive or negative tone. 1. A resist composition comprising a base polymer and a quencher , the quencher being an amine compound having an iodine-substituted aromatic ring bonded to the nitrogen atom via a C-Cdivalent hydrocarbon group which may contain at least one moiety selected from ester bond and ether bond.3. The resist composition of claim 1 , further comprising an acid generator capable of generating a sulfonic acid claim 1 , imide acid or methide acid.4. The resist composition of claim 1 , further comprising an organic solvent.6. The resist composition of which is a chemically amplified positive resist composition.7. The resist composition of wherein the base polymer is free of an acid labile group.8. The resist composition of which is a chemically amplified negative resist composition.10. The resist composition of claim 1 , further comprising a surfactant.11. The resist composition of claim 1 , further comprising a quencher other than the amine compound.12. A process for forming a pattern comprising the steps of applying the resist composition of onto a substrate claim 1 , baking to form a resist film claim 1 , exposing the resist film to high-energy radiation claim 1 , and developing the exposed resist film in a developer.13. The process of wherein the high-energy radiation is ArF excimer laser radiation of wavelength 193 nm or KrF excimer laser radiation of wavelength 248 nm.14. The process of wherein the high-energy radiation is EB or EUV of wavelength 3 to 15 nm. This non-provisional application claims priority under 35 U.S.C. § 119(a) on Patent Application No. 2018-150050 filed in Japan on Aug. 9, 2018, the entire contents of which are hereby incorporated by reference.This ...

Подробнее
26-02-2015 дата публикации

SMALL MOLECULE INDUCERS OF GDNF AS POTENTIAL NEW THERAPEUTICS FOR NEUROPSYCHIATRIC DISORDERS

Номер: US20150056699A1

This invention provides a compound having the structure 34-. (canceled)8. (canceled)1112-. (canceled)14. (canceled)1822-. (canceled)2426-. (canceled)2832-. (canceled)34. (canceled)36. (canceled)3844-. (canceled)4647-. (canceled)5052-. (canceled)54. (canceled) Throughout this application, certain publications are referenced in parentheses. Full citations for these publications may be found immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to describe more fully the state of the art to which this invention relates.Neurotrophic factors play important roles not only in the development of the nervous system, but also in maintenance of its function and plasticity. GDNF (Glial cell line-Derived Neurotrophic Factor) is essential for growth, development and plasticity of dopamine and motor neurons as well as other brain cell populations (Airaksinen, M. S. et al. 2002). In the brain, GDNF is released by both neurons and glia cells. Although the signaling mechanisms underlying the expression and release of GDNF are not fully mapped, the released GDNF exerts its function on the brain cells and neurocircuitry through a receptor complex, comprised of GFRα1 (GDNF Family Receptor α1) and receptor tyrosine kinase RET (Trupp, M. et al. 1997). On the basis of the trophic and repair effects GDNF has on neural cells, it was considered as a potential therapeutic agent for several neurological disorders. However, GDNF is a protein and thus not readily administered to the brain. Consequently, small molecule inducers of GDNF release are of interest as potential therapeutics, most notably in the context of Parkinson's disease and neuropathic pain. In the latter case, GDNF's effectiveness has been ascribed to the ability of GDNF signaling to reset the function of several sodium channel subunits (modified in response to injury) (Boucher, T. J. et al. 2000).Recently, it has been shown ...

Подробнее
10-03-2022 дата публикации

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Номер: US20220073508A1
Принадлежит: Genzyme Corporation

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer. 1248-. (canceled)250. The method of claim 249 , wherein the disease or disorder is cancer a metabolic disorder claim 249 , or a neuropathic disease.251253-. (canceled)254. The method of claim 250 , wherein the neuropathic disease is Parkinson's disease.255295-. (canceled)296. The method of claim 249 , wherein n is 1 claim 249 , t is 0 claim 249 , y is 1 claim 249 , and z is 1.297. The method of claim 249 , wherein m is 1 claim 249 , E is O claim 249 , Xis O claim 249 , and Xis NH.298. The method of claim 249 , wherein Ais (C-C)heteroaryl.299. The method of claim 298 , wherein Ais thiophene claim 298 , thiazole claim 298 , isothiazole claim 298 , furane claim 298 , oxazole claim 298 , isoxazole claim 298 , pyrrole claim 298 , imidazole claim 298 , pyrazole claim 298 , triazole claim 298 , pyridine claim 298 , pymiridine claim 298 , pyridazine claim 298 , indole claim 298 , benzothiazole claim 298 , benzopyrazole claim 298 , benzoimidazole claim 298 , benzofuran claim 298 , benzooxazole or benzoisoxazole.300. The method of claim 249 , wherein Ais (C-C)aryl.301. The method of claim 249 , wherein the compound is administered at a dosage of from 0.5 mg/kg to 300 mg/kg by intraperitoneal claim 249 , oral or equivalent administration from one to five times daily.302. The method of claim 249 , wherein the compound is administered at a dose of from about 10 mg/day to about 500 mg/day.303. The method of claim 249 , wherein the compound is administered in an oral dose of from about 1 mg/kg/day to about 100 mg/kg/day.305. The compound of claim 304 , wherein n is 1 claim 304 , t is 0 claim 304 , y is 1 claim 304 , and z is 1.306. The compound of claim 304 , wherein Xis a direct bond.307. The compound of claim 304 , ...

Подробнее
05-03-2015 дата публикации

AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS

Номер: US20150065537A1
Принадлежит:

The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory. 12. A medicament comprising at least one compound as claimed in and at least one pharmaceutically acceptable claim 1 , essentially nontoxic carrier or excipient.13. A method for improving perception claim 1 , concentration claim 1 , learning and/or memory comprising administering to a human or animal an effective amount of a compound of .14. A method for the treatment and/or prophylaxis of impairments of perception claim 1 , concentration claim 1 , learning and/or memory comprising administering to a human or animal an effective amount of a compound of .15. A method for the treatment and/or prophylaxis of impairments of perception claim 12 , concentration claim 12 , learning and/or memory comprising administering to a human or animal an effective amount of a medicament of . The invention relates to novel benzothiophene-, benzofuran- and indoleureas, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.Nicotinic acetylcholine receptors (nAChR) form a large family of ion channels which are activated by the messenger acetylcholine which is produced in the body (Galzi et al., 1995, 34, 563-582). A functional nAChR consists of five subunits which may be different (certain combinations of α1-9 and (β1-4,γ,δ,ε subUnits) or identical (α 7-9). This leads˜to the formation of a diversity of subtypes which differ in the distribution in the muscles, the nervous system and other organs (McGehee et al, 1995, 57, 521-546). Activation of nAChR leads to influx of cations into the cell and to stimulation of nerve cells or muscle cells. Selective activation of individual nAChR subtypes restricts this ...

Подробнее
10-03-2016 дата публикации

TARGETED NITROXIDE AGENTS

Номер: US20160068556A1

A compound having a structure of: 18-. (canceled)13. The compound of claim 9 , further comprising a detector label moiety coupled to the compound.14. The compound of claim 14 , wherein the detector label moiety comprises a fluorophore covalently bonded to the compound.15. The compound of claim 9 , wherein the compound is in the form of a nitroxide claim 9 , a hydroxylamine claim 9 , or a nitroxonium ion.16. The compound of claim 9 , wherein the compound is in the form of a pharmaceutically acceptable salt or ester thereof.17. A pharmaceutical composition comprising a compound of claim 9 , and at least one pharmaceutically acceptable additive.19. The method of claim 18 , wherein the compound is administered after the subject has been exposed to radiation.20. The method of claim 18 , wherein the compound is administered to the subject prior to the subject's exposure to radiation.21. The method of claim 18 , wherein the radiation is ionizing radiation.23. The method of claim 18 , wherein the compound is preferentially delivered to the mitochondria. This is a divisional application of U.S. application Ser. No. 14/000,173, filed Aug. 16, 2013, which is the U.S. National Stage of International Application No. PCT/US2012/025586, filed Feb. 17, 2012, which was published in English under PCT Article 21(2), which in turn claims the benefit of U.S. Provisional Application No. 61/444,492, filed Feb. 18, 2011, U.S. Provisional Application No. 61/454,003, filed Mar. 18, 2011, and U.S. Provisional Application No. 61/474,915, Apr. 13, 2011, all of which are incorporated herein by reference in their entireties.This invention was made with government support under grant number AI068021 and grant number GM067082 awarded by the National Institutes of Health, Department of Health and Human Services. The government has certain rights in the invention.Provided herein are novel compounds and compositions of matter comprising a nitroxide group-containing cargo (or “nitroxide containing ...

Подробнее
08-03-2018 дата публикации

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

Номер: US20180065957A1
Принадлежит: Genzyme Corporation

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment of metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, cystic disease and for the treatment of cancer. 2246-. (canceled)247. A compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , selected from the group consisting of:1-azabicyclo[2.2.2]oct-3-yl [2-(2,4′-difluorobiphenyl-4-yl)propan-2-yl]carbamate;1-azabicyclo[2.2.2]oct-3-yl {2-[4-(1,3-benzothiazol-6-yl)phenyl]propan-2-yl}carbamate;1-azabicyclo[3.2.2]non-4-yl {1-[5-(4-fluorophenyl)pyridin-2-yl]cyclopropyl}carbamate;1-azabicyclo[2.2.2]oct-3-yl {1-[3-(4-fluorophenoxy)phenyl]cyclopropyl}carbamate;1-azabicyclo[2.2.2]oct-3-yl {1-[4-(1,3-benzothiazol-5-yl)phenyl]cyclopropyl)}carbamate;1-azabicyclo[2.2.2]oct-3-yl [1-(4′-fluoro-3′-methoxybiphenyl-4yl)cyclopropyl]carbamate;1-azabicyclo[2.2.2]oct-3-yl [3-(4′-fluorobiphenyl-4-yl)oxetan-3-yl]carbamate;1-azabicyclo[2.2.2]oct-3-yl {1-[6-(4-fluorophenoxy)pyridin-2-yl]cyclopropyl}) carbamate;1-azabicyclo[2.2.2]oct-3-yl [3-(4′-fluorobiphenyl-4-yl)pentan-3-yl]carbamate;1-azabicyclo[2.2.2]oct-3-yl {2-[2-(4-fluorophenyl)-2H-indazol-6-yl]propan-2 yl}carbamate;1-azabicyclo[2.2.2]oct-3-yl {2-[2-(1H-pyrrol-1-yl)pyridin-4-yl]propan-2-yl}carbamate;1-(3-ethyl-1-azabicyclo[2.2.2]oct-3-yl)-3-[1-(4′-fluorobiphenyl-4-yl)cyclopropyl]urea;N-(1-azabicyclo[2.2.2]oct-3-yl)-N′-[1-(4′-fluorobiphenyl-4yl)cyclopropyl]ethanediamide;1-azabicyclo[2.2.2]oct-3-yl (1-{4[(4,4difluorocyclohexyl)oxy]phenyl}cyclopropyl) carbamate;1-(4-methyl-1-azabicyclo[3.2.2]non-4-yl)-3-[1-(5-phenylpyridin-2-yl)cyclopropyl]urea;1-[1-(4′-fluorobiphenyl-4-yl)cyclopropyl]-1-methyl-3-(3-methyl-1-azabicyclo[2.2.2]oct-3-yl)urea;1-[1-(4′-fluorobiphenyl-4-yl)cyclopropyl]-1-methyl-3-(3-methyl-1-azabicyclo[2.2.2]oct-3-yl)urea;1-{2-[4′-(2-methoxyethoxy)biphenyl-4-yl]propan-2-yl}-3-(3-methyl-1-azabicyclo[2.2.2]oct-3-yl)urea;2-(1-azabicyclo[3.2.2] ...

Подробнее
15-03-2018 дата публикации

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

Номер: US20180072735A1
Принадлежит:

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 1203-. (canceled)205. The method of claim 204 , wherein Ring B is a 3-7 membered fully saturated claim 204 , partially unsaturated claim 204 , or aromatic monocyclic ring having 0-3 heteroatoms selected from the group consisting of oxygen claim 204 , nitrogen claim 204 , and sulfur.208. The method of claim 204 , wherein the cancer has a defect in a base excision repair protein.209. The method of claim 207 , wherein the cancer has a defect in a base excision repair protein.210. The method of claim 208 , wherein the base excision repair protein is selected from UNG claim 208 , SMUG1 claim 208 , MBD4 claim 208 , TDG claim 208 , OGG1 claim 208 , MYH claim 208 , NTH1 claim 208 , MPG claim 208 , NEIL1 claim 208 , NEIL2 claim 208 , NEIL3 (DNA glycosylases); APE1 claim 208 , APEX2 (AP endonucleases); LIG1 claim 208 , LIG3 (DNA ligases I and III); XRCC1 (LIG3 accessory); PNK claim 208 , PNKP (polynucleotide kinase and phosphatase); PARP1 claim 208 , PARP2 (Poly(ADP-Ribose) Polymerases); PolB claim 208 , PolG (polymerases); FEN1 (endonuclease) or Aprataxin.211. The method of claim 209 , wherein the base excision repair protein is selected from UNG claim 209 , SMUG1 claim 209 , MBD4 claim 209 , TDG claim 209 , OGG1 claim 209 , MYH claim 209 , NTH1 claim 209 , MPG claim 209 , NEIL1 ...

Подробнее
15-03-2018 дата публикации

5HT3 RECEPTOR ANTAGONISTS

Номер: US20180072758A1
Принадлежит:

The present invention provides compounds of the formula: 2. The compound or pharmaceutically acceptable salt of claim 1 , wherein Ris selected from the group consisting of furanyl claim 1 , pyrrolyl claim 1 , imidazolyl claim 1 , oxazolyl claim 1 , isoxazolyl claim 1 , oxadiazolyl claim 1 , thiazolyl claim 1 , isothiazolyl claim 1 , thiadiazolyl claim 1 , triazolyl claim 1 , tetrazolyl claim 1 , pyrazinyl claim 1 , pyridazinyl claim 1 , each optionally substituted with one or two substituents independently selected from Calkyl claim 1 , Chaloalkyl claim 1 , Chaloalkoxy claim 1 , Calkoxy claim 1 , hydroxy claim 1 , cyano claim 1 , or halo.3. The compound or pharmaceutically acceptable salt of claim 1 , wherein Z is O.4. The compound or pharmaceutically acceptable salt of claim 1 , wherein Z is NH.5. The compound or pharmaceutically acceptable salt of claim 1 , wherein Ris a ring of formula (a) claim 1 , (d) claim 1 , (e) claim 1 , (f) claim 1 , or (g).6. The compound or pharmaceutically acceptable salt of claim 5 , wherein Ris a ring of formula (a) or (d).7. The compound or pharmaceutically acceptable salt of claim 5 , wherein Ris a ring of formula (e) claim 5 , (f) claim 5 , or (g).8. The compound or pharmaceutically acceptable salt of claim 5 , wherein Ris a ring of formula (e).9. The compound or pharmaceutically acceptable salt of claim 1 , wherein each Ris hydrogen.10. The compound or pharmaceutically acceptable salt of claim 1 , wherein Ris methyl.11. The compound or pharmaceutically acceptable salt of claim 1 , wherein is where all of X-Xare CRand each Ris hydrogen.12. The compound or pharmaceutically acceptable salt of claim 11 , wherein Xis N.13. The compound or pharmaceutically acceptable salt of claim 11 , wherein Xis CRand Ris hydrogen.14. A compound of selected from:(1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 5-fluoro-1-(2,2,2-trifluoroethyl)-1H-indole-3-carboxylate;(1R,3R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 5-fluoro-1-((R)-tetrahydrofuran-3- ...

Подробнее
19-03-2015 дата публикации

Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV

Номер: US20150080577A1
Принадлежит:

The present invention relates to the cinchonidine salt 2. The process of wherein Ris methyl.3. The process of or claim 1 , wherein amide-forming reaction is conducted in the presence of an amide-coupling reagent in a reaction-inert solvent claim 1 , optionally in the presence of a base.4. The process of wherein the solvent comprises halogenated hydrocarbons such as dichloromethane (DCM) or chloroform claim 3 , ethers such as tetrahydrofuran (THF) or 2-methyltetrahydrofuran (MeTHF) claim 3 , alcohols such as methanol or ethanol claim 3 , hydrocarbon solvents such as toluene or xylene claim 3 , dipolar aprotic solvents such as DMF claim 3 , DMA claim 3 , acetonitrile claim 3 , or mixtures thereof.5. The process of wherein the amide forming agent comprises agents such as N-ethoxycarbonyl-2-ethoxy-1 claim 3 ,2-dihydroquinoline (EEDQ) claim 3 , N-isopropoxy-carbonyl-2-isopropoxy-1 claim 3 ,2-dihydroquinoline (IIDQ) claim 3 , N claim 3 ,N claim 3 ,N′ claim 3 ,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (HATU) claim 3 , benzotriazol-1-yl-oxy-tris-pyrrolidino-phosphonium hexafluorophosphate claim 3 , CDI claim 3 , 1-ethyl-3-(3-di-methylaminopropyl) carbodiimide (EDCI) or its hydrochloride claim 3 , dicyclohexyl-carbodiimide (DCC) claim 3 , 1 claim 3 ,3-diisopropylcarbodiimide claim 3 , or O-benzotriazole-N claim 3 ,N claim 3 ,N′ claim 3 ,N′-tetramethyl-uronium-hexafluorophosphate (HBTU) claim 3 , optionally in the presence of a catalyst such as 1-hydroxybenzotriazole (HOBt) or 4-dimethylaminopyridine (DMAP).6. The process of wherein the optional base is a tertiary amine claim 3 , such as triethylamine claim 3 , N-methylmorpholine claim 3 , N claim 3 ,N-diisopropylethylamine.9. The process of claim 8 , wherein a suspension of cinchonidine is added to a solution of (XV) at slightly elevated temperature and subsequently allowing the mixture to cool whereupon the desired product (XXa) crystallizes.10. The process of or claim 8 , wherein (XV) is ...

Подробнее
05-06-2014 дата публикации

NOVEL COMPOUNDS

Номер: US20140155373A1
Принадлежит: CHIESI FARMACEUTICI S.p.A.

Compounds of formula (I) described herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction. 6. A compound claim 1 , N-oxide claim 1 , or pharmaceutically acceptable salt according to claim 1 , which is a compound selected from the group consisting of[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)ethyl](2S)-3-[3-[[2-oxo-1-phenyl-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]carbamoyl]phenyl]sulfonylthiazolidine-2-carboxylate;[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)ethyl](2S)-3-[3-[(N-[(3R)-quinuclidin-3-yl]oxycarbonyl anilino)methyl]benzoyl]thiazolidine-2-carboxylate;[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)ethyl](2S)-1-[3-[[2-oxo-1-phenyl-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]amino]phenyl]sulfonylpyrrolidine-2-carboxylate;[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)ethyl](2R)-1-[3-[[1-(3-fluorophenyl)-2-oxo-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]amino]phenyl]sulfonylpyrrolidine-2-carboxylate;[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)ethyl](2S)-3-[3-[[2-oxo-1-phenyl-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]amino]phenyl]sulfonylthiazolidine-2-carboxylate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl) ethyl](2S)-3-[3-[[2-oxo-1-phenyl-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]carbamoyl]phenyl]sulfonylthiazolidine-2-carboxylate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl](2S)-1-[3-[(2-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoyl]piperidine-2-carboxylate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl](4R)-3-[3-[(2-fluoro-N-[( ...

Подробнее
05-06-2014 дата публикации

BRIDGED BICYCLIC ARYL AND BRIDGED BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS

Номер: US20140155386A1
Принадлежит: Rigel Pharmaceuticals, Inc.

Bridged bicyclic aryl or heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed. 2. The compound of selected from:{'sup': '3', '1-(1,4-ethano-8-phenyl-1,2,3,4-tetrahydro-1,5-naphthyridin-6-yl)-N-(3-fluoro-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)phenyl)-1H-1,2,4-triazole-3,5-diamine;'}{'sup': '3', '1-(1,4-ethano-8-thiophen-2-yl-1,2,3,4-tetrahydro-1,5-naphthyridin-6-yl)-N-(3-fluoro-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)phenyl)-1H-1,2,4-triazole-3,5-diamine;'}{'sup': '3', '1-(1,4-ethano-8-pyridin-4-yl-1,2,3,4-tetrahydro-1,5-naphthyridin-6-yl)-N-(3-fluoro-4-(4-(pyrrolidin-1-yl)piperidin-1-yl)phenyl)-1H-1,2,4-triazole-3,5-diamine;'}{'sup': '3', '1-(1,4-ethano-8-phenyl-1,2,3,4-tetrahydro-1,5-naphthyridin-6-yl)-N-(3-fluoro-4-(3-carboxypiperazin-1-yl)phenyl)-1H-1,2,4-triazole-3,5-diamine;'}{'sup': '3', '1-(1,4-ethano-8-phenyl-1,2,3,4-tetrahydro-1,5-naphthyridin-6-yl)-N-(4-(4-methylpiperazin-1-yl)phenyl)-1H-1,2,4-triazole-3,5-diamine;'}{'sup': '3', '1-(1,4-ethano-8-phenyl-1,2,3,4-tetrahydro-1,5-naphthyridin-6-yl)-N-(3-fluoro-4-(4-bicyclo[2.2.1]heptan-2-yl piperazin-1-yl)phenyl)-1H-1,2,4-triazole-3,5-diamine;'}{'sup': '3', '1-(1,4-ethano-8-phenyl-1,2,3,4-tetrahydro-1,5-naphthyridin-6-yl)-N-(3-fluoro-4-(4-cyclohexyl piperazin-1-yl)phenyl)-1H-1,2,4-triazole-3,5-diamine;'}{'sup': '3', '1-(1,4-ethano-8-phenyl-1,2,3,4-tetrahydro-1,5-naphthyridin-6-yl)-N-(3-fluoro-4-(4-(4-methylpiperazin-1-yl)piperidin-1yl)phenyl)-1H-1,2,4-triazole-3,5-diamine;'}{'sup': '3', '1-(1,4-ethano-8-phenyl-1,2,3,4-tetrahydro-1,5-naphthyridin-6-yl)-N-(3-fluoro-4-(4-ethyloxycarbonylmethylpiperazin-1-yl)phenyl)-1H-1,2,4-triazole-3,5-diamine;'}{'sup': '3', '1-(1,4-ethano-8-phenyl-1,2,3,4-tetrahydro-1,5-naphthyridin-6-yl)-N-(3-fluoro-4-(4-carboxymethylpiperazin-1-yl) ...

Подробнее
05-06-2014 дата публикации

NOVEL COMPOUNDS

Номер: US20140155427A1
Принадлежит: CHIESI FARMACEUTICI S.p.A.

Compounds of formula (I) described herein are inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of diseases of the respiratory tract characterized by airway obstruction. 7. A compound claim 1 , N-oxide claim 1 , deuterated derivative claim 1 , or a pharmaceutically acceptable salt according to which is a compound selected from the group consisting of:(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]3-[(4-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]3-[(2-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]3-[(3-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]3-[(2-methoxy-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]3-[(3-methoxy-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]3-[(4-methoxy-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]4-[(N-[(3R)-quinuclidin-3-yl]oxycarbonylanilino)methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]4-[(2-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]4-[(4-fluoro-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]4-[(2-methoxy-N-[(3R)-quinuclidin-3-yl]oxycarbonyl-anilino)methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido- ...

Подробнее
05-06-2014 дата публикации

NOVEL COMPOUNDS

Номер: US20140155428A1
Принадлежит: CHIESI FARMACEUTICI S.p.A

Compounds of formula (I) defined herein are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists and are useful for the prevention and/or treatment of a disease of the respiratory tract characterized by airway obstruction. 4. A compound claim 1 , N-oxide claim 1 , deuterated derivative claim 1 , or pharmaceutically acceptable salt according to claim 1 , wherein{'sub': 5', '1', '6', '1', '6, 'Ris (C-C) haloalkyl or (C-C) alkyl,'}{'sub': 4', '3', '7', '1', '6', '3', '7, 'Ris (C-C) cycloalkyl or (C-C) alkyl which is optionally substituted by (C-C) cycloalkyl.'}7. A compound claim 1 , N-oxide claim 1 , deuterated derivative claim 1 , or pharmaceutically acceptable salt according to claim 1 , which is a compound selected from the group consisting of:[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-[[[2-oxo-1-phenyl-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]amino]methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-[[[1-(2-methoxyphenyl)-2-oxo-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]amino]methyl]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-[[2-oxo-1-phenyl-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]amino]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl] 3-fluoro-4-[[2-oxo-1-phenyl-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]amino]benzoate;[(1S)-1-[3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl]-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)ethyl] 4-[[1-(3-fluorophenyl)-2-oxo-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]amino]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]-4-[[1-(2-fluorophenyl)-2-oxo-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]amino]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4-dimethoxyphenyl)ethyl]-4-[[1-(3-fluorophenyl)-2-oxo-2-[(3R)-quinuclidin-3-yl]oxy-ethyl]amino]benzoate;[(1S)-2-(3,5-dichloro-1-oxido-pyridin-1-ium-4-yl)-1-(3,4- ...

Подробнее
05-06-2014 дата публикации

Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine

Номер: US20140155429A1
Автор: Koenig Gerhard
Принадлежит: EnVivo Pharmaceuticals, Inc.

A method for improving cognition comprising co-administering to a subject an alpha 7 agonist, or a pharmaceutically acceptable salt thereof and a tobacco-free nicotine dosage is described together with related compositions. 2. The method according to wherein Ris hydrogen claim 1 , Ris hydrogen claim 1 , A is sulfur claim 1 , and Z is halogen claim 1 , formyl claim 1 , carbamoyl claim 1 , cyano claim 1 , trifluoromethyl claim 1 , trifluoromethoxy claim 1 , nitro claim 1 , amino claim 1 , formamido claim 1 , acetamido claim 1 , (C-C)alkyl claim 1 , (C-C)alkyoxy claim 1 , (C-C)alkylthio claim 1 , or (C-C)alkylamino.3. The method according to wherein Z is heteroaryl-carbonylamino claim 1 , arylcarbonylamino claim 1 , (C-C)alkylsulfonylamino claim 1 , di(arylsulfonyl)amino claim 1 , (C-C)cycloalkylcarbonylmethyl or amino(hydroxyimino).4. The method according to wherein Z is halogen claim 1 , cyano claim 1 , trifluoromethyl claim 1 , trifluoromethoxy claim 1 , methyl claim 1 , ethyl claim 1 , methoxy claim 1 , or ethoxy.5. The method according to wherein the compound of formula (I) is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide.6. The method of wherein the subject has been diagnosed with Alzheimer's disease or pre-Alzheimer's disease.7. The method of wherein the subject has been diagnosed with mild to moderate Alzheimer's disease.8. The method of wherein the subject has been diagnosed with moderate to severe Alzheimer's disease.9. The method of wherein the subject has been diagnosed with schizophrenia or schizoaffective disorder.10. The method of claim 1 , wherein the method improves one or more of: learning claim 1 , delayed memory claim 1 , attention claim 1 , working memory claim 1 , visual learning claim 1 , speed of processing claim 1 , vigilance claim 1 , verbal learning claim 1 , visual motor function claim 1 , social cognition claim 1 , long term memory or executive function.11. The method of wherein the (R)-7-chloro-N-(quinuclidin-3-yl)benzo[ ...

Подробнее
24-03-2016 дата публикации

TRICYCLIC SULPHONAMIDE COMPOUNDS AND METHODS OF MAKING AND USING SAME

Номер: US20160083362A1
Принадлежит:

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. 1. A compound selected from the group consisting of: (1aR ,7bS)-5-[2-(2-diethylaminomethylcyclopropyl)-4-fluoro-benzenesulfonylamino]-1 ,1a ,2 ,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid , or enantiomers thereof; (1aR ,7bS)-5-{4-fluoro-2-[2-(pyrrolidin-1-ylmethyl)cyclopropyl]-benzenesulfonylamino}-1 ,1a ,2 ,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aR ,7bS)-5-[2-(3-diethylamino-2 ,2-dimethylpropyl)-4-fluorobenzenesulfonylamino]-1 ,1a ,2 ,7b-tetrahydrocyclopro-[c]chromene-4-carboxylic acid; (1aR ,7bS)-5-[4-fluoro-2-((R)-pyrrolidin-3-ylmethyl)benzene-sulfonylamino]-1 ,1a ,2 ,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid; (1aR ,7bS)-5-[4-fluoro-2-((S)-pyrrolidin-3-ylmethyl)benzene-sulfonylamino]-1 ,1a ,2 ,7b-tetrahydrocyclopropa [c]chromene-4-carboxylic acid; (1aR ,7bS)-5-{4-fluoro-2-[(R)-1-(2-hydroxy-2-methylpropyl)-pyrrolidin-3-ylmethyl]benzenesulfonylamino}-1 ,1a ,2 ,7b-tetrahydrocyclopropa [c]chromene-4-carboxylic acid; (1aR ,7bS)-5-[2-(1-azabicyclo[2.2.2]oct-3-ylmethyl)-4-fluoro-benzenesulfonylamino]-1 ,1a ,2 ,7b-tetrahydro cyclopropa-[c]chromene-4-carboxylic acid; (1aR ,7bS)-5-[2-((Z)-1-azabicyclo[2.2.2]oct-3-ylidenemethyl)-4-fluorobenzenesulfonylamino]-1 ,1a ,2 ,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aR ,7bS)-5-[2-((E)-1-azabicyclo[2.2.2]oct-3-ylidenemethyl)-4-fluorobenzenesulfonylamino]-1 ,1a ,2 ,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aR ,7bS)-5-{2-[(E)-(1-ethylpiperidin-3-ylidene)methyl]-4-fluorobenzenesulfonylamino}-1 ,1a ,2 ,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylic acid; (1aR ,7bS)-5-{2-[(Z)-(1-ethylpiperidin-3-ylidene)methyl]-4-fluorobenzenesulfonylamino}-1 ,1a ,2 ,7b-tetrahydrocyclopropa-[c]chromene-4- ...

Подробнее
12-06-2014 дата публикации

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Номер: US20140161736A1
Автор: Linney Ian, RANCATI Fabio
Принадлежит: CHIESI FARMACEUTICI S.p.A

Compounds of formula (I) described herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases. 6. A pharmaceutical composition claim 1 , comprising a compound or pharmaceutically acceptable salt according to and one or more pharmaceutically acceptable carriers and/or excipients.7. A method for the prevention and/or treatment of a broncho-obstructive or inflammatory disease claim 1 , comprising administering an effective amount of a compound or pharmaceutically acceptable salt according to to a subject in need thereof.8. A method according to claim 7 , wherein said broncho-obstructive or inflammatory disease is asthma claim 7 , chronic bronchitis claim 7 , or chronic obstructive pulmonary disease.9. A combination claim 1 , comprising a compound or pharmaceutically acceptable salt according to and one or more active ingredients selected from the group consisting of a beta2-agonist claim 1 , antimuscarinic agent claim 1 , mitogen-activated protein kinase (P38 MAP kinase) inhibitor claim 1 , nuclear factor kappa-B kinase subunit beta (IKK2) inhibitor claim 1 , human neutrophil elastase (FINE) inhibitor claim 1 , phosphodiesterase 4 (PDE4) inhibitor claim 1 , leukotriene modulator claim 1 , non-steroidal anti-inflammatory agent (NSAID) claim 1 , antitussive agent claim 1 , mucus regulator claim 1 , mucolytic claim 1 , expectorant/mucokinetic modulator claim 1 , peptide mucolytic claim 1 , antibiotic claim 1 , inhibitor of JAK claim 1 , SYK inhibitor claim 1 , inhibitor of PI3Kdelta or PI3Kgamma claim 1 , corticosteroid claim 1 , and M3-antagonist/PDE4-inhibitor (MAPI).10. A pharmaceutical composition according to claim 6 , which is in a form suitable to be administered by inhalation.11. A pharmaceutical composition according to claim 6 , which is an inhalable powder claim 6 , a propellant-containing metering aerosol claim 6 , or a propellant- ...

Подробнее
31-03-2022 дата публикации

POLYMORPHIC FORMS OF A SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUND

Номер: US20220098186A1
Принадлежит: Purdue Pharma L.P.

Provided herein are novel crystalline forms of a crystalline compound of Formula (I), which modulates the ORL-1 receptor. The crystalline compounds of Formula (I), compositions thereof, and methods of using thereof that are described herein are particularly useful for treatment, prevention, and management of several sleep disorders. 2. The crystalline compound of claim 1 , further comprising peaks at diffraction angles (2Θ±0.2°) of 21.1 and 22.2.3. The crystalline compound of or claim 1 , further comprising peaks at diffraction angles (2Θ±0.2°) of 7.4 claim 1 , 9.6 claim 1 , 14.7 claim 1 , and 16.7.4. The crystalline compound of claim 1 , that produces a powder X-ray diffraction spectrum comprising peaks at diffraction angles (2Θ±0.2°) of 7.4 claim 1 , 9.6 claim 1 , 14.7 claim 1 , 16.7 claim 1 , 17.1 claim 1 , 18.5 claim 1 , 19.3 claim 1 , 21.1 claim 1 , and 22.2.7. The crystalline compound of claim 6 , wherein at least about 95% by wt. of the crystalline compound of Formula (I) is crystalline Form A.8. The crystalline compound of claim 6 , wherein at least about 98% by wt. of the crystalline compound of Formula (I) is crystalline Form A.9. The crystalline compound of claim 6 , wherein the crystalline compound of Formula (I) is substantially pure crystalline Form A.10. The crystalline compound of any one of to claim 6 , wherein the crystalline compound has a particle size Dof 15 μm.11. The crystalline compound of any one of to claim 6 , wherein the crystalline compound has a particle size Dof 8 μm.14. A pharmaceutical composition comprising a crystalline compound according to any one of to claim 6 , and at least one pharmaceutically acceptable excipient.16. A dosage unit comprising from about 0.16 mg to about 8.0 mg of a crystalline compound according to any one of to .18. The dosage unit of or claim 6 , wherein the dosage unit is a solid oral dosage form.19. The dosage unit of claim 18 , wherein the solid oral dosage for is a tablet or capsule.20. The dosage unit ...

Подробнее
12-06-2014 дата публикации

PIM KINASE INHIBITORS AND PREPARATION METHODS AND USE IN MEDICINAL MANUFACTURE THEREOF

Номер: US20140162999A1
Автор: Ge Yu
Принадлежит: Jikai Biosciences, Inc.

PIM kinase inhibitor compound having a structure as represented by Formula I, and isomers, diastereomers, enantiomers, tautomers, and pharmaceutically acceptable salts of the compounds as represented by Formula I. The compounds significantly inhibit the Pim kinase activity and are used to prepare drugs to treat PIM kinase mediated diseases, such as cancers, autoimmune diseases, allergic reactions, or organ transplant rejection. Also provided are methods for preparing the compounds represented by Formula I. 2. The compound according to claim 1 , wherein J claim 1 , J claim 1 , and the carbon atom to which Jand Jare attached are joined together to form a benzene ring or a naphthlene; or J claim 1 , J claim 1 , the carbon atom to which Jand Jare attached claim 1 , and at least one heteroatom are joined together to form the C-Cmembered aromatic heterocycle that is a pyridine claim 1 , pyrimidine claim 1 , pyrazine claim 1 , imidazole claim 1 , thiazole claim 1 , isoxazole claim 1 , oxazole claim 1 , or pyrrole claim 1 , on the aromatic ring or the aromatic heterocycle.3. The Pim kinase inhibitor according to claim 1 , wherein the Pim kinase inhibitor is the compound as represented by Formula I or an isomer claim 1 , diastereomer claim 1 , enantiomer claim 1 , tautomer claim 1 , or a pharmaceutically acceptable salt of the compound as represented by Formula 1.4. The Pim kinase inhibitors according to claim 1 , wherein the compound is 2-(2 claim 1 ,6-difluorophenyl)-N-(4-(pyrrolidin-3-yloxy)pyrimidin-5-yl)thiazole-4-carboxamide (1); N-(4-(azepan-4-yloxy)pyrimidin-5-yl)-2-(2 claim 1 ,6-difluorophenyl)thiazole-4-carboxamide (2); 2-(2 claim 1 ,6-difluorophenyl)-N-(4-(piperidin-4-yloxy)pyrimidin-5-yl)thiazole-4-carboxamide (3); 5-amino-2-(2 claim 1 ,6-difluorophenyl)-N-(4-(piperidin-4-yloxy)pyrimidin-5-yl)thiazole-4-carboxamide (4); 2-(2 claim 1 ,6-difluorophenyl)-N-(4-((4-hydroxycyclohexyl)oxy)pyrimidin-5-yl)thiazole-4-carboxamide (5); 2-(2 claim 1 ,6-difluorophenyl)-N-(4-( ...

Подробнее
12-06-2014 дата публикации

COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE

Номер: US20140163000A1
Принадлежит:

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 2. The compound of claim 1 , wherein Ris fluoro.3. The compound of claim 1 , wherein Ris —CHCN claim 1 , —C(CH)CN or —CH(Calkyl)CN.4. The compound of claim 1 , wherein Ris chloro.5. The compound of claim 1 , wherein Ris independently selected from —CF claim 1 , —NH(Calkyl) claim 1 , chloro claim 1 , or H.6. The compound of claim 5 , wherein Ris H.7. The compound of claim 5 , wherein Ris -chloro.8. The compound of claim 5 , wherein Ris independently selected from H claim 5 , chloro claim 5 , fluoro claim 5 , CF claim 5 , —CN claim 5 , cyclopropyl claim 5 , or Calkyl.9. The compound of claim 8 , wherein Ris independently selected from H claim 8 , chloro claim 8 , or fluoro.10. The compound of claim 9 , wherein Ris H.11. The compound of claim 9 , wherein Ris chloro.12. The compound of claim 9 , wherein Ris fluoro.14. The compound of claim 13 , wherein Ris —O—.15. The compound of claim 14 , wherein Jis independently selected from —(Calkyl) claim 14 , —(Calkyl)N(Calkyl) claim 14 , —(Calkyl)O(Calkyl)N(Calkyl) claim 14 , (Calkyl)OH claim 14 , —(Calkyl)NH claim 14 , or —(Calkyl)O(Calkyl).16. The compound of claim 14 , wherein Jis Q.17. The compound of claim 16 , wherein Qis a 3-7 membered fully saturated claim 16 , partially unsaturated claim 16 , or aromatic monocyclic ring having ...

Подробнее
26-03-2015 дата публикации

SYNTHESIS OF MSE-FRAMEWORK TYPE MOLECULAR SIEVES

Номер: US20150087841A1

A method of synthesizing a crystalline molecular sieve having an MSE framework type comprises crystallizing a reaction mixture comprising a source of water, a source of an oxide of a tetravalent element, Y, selected from at least one of silicon, tin, titanium, vanadium, and germanium, optionally a source of a trivalent element, X, a source of an alkali or alkaline earth metal, M, and a source of organic dications, Q, such as 3-hydroxy-1-(4-(1-methylpiperidin-1-ium-1-yl)butyl)quinuclidin-1-ium, 3-hydroxy-1-(5-(1-methylpiperidin-1-ium-1-yl)pentyl)quinuclidin-1-ium, 1,1′-(butane-1,4-diyl)bis(1-methylpiperidin-1-ium), 1,1′-(pentane-1,5-diyl)bis(1-methylpiperidin-1-ium), 1,1′-(hexane-1,6-diyl)bis(1-methylpiperidin-1-ium), and 1,1′-((3as,6as)-octahydropentalene-2,5-diyl)bis(1-methylpiperidin-1-ium). 2. A dication according to claim 1 , which is a 3-hydroxy-1-(4-(1-methylpiperidin-1-ium-1-yl)butyl)quinuclidin-1-ium dication of Formula (III) or a 3-hydroxy-1-(5-(1-methylpiperidin-1-ium-1-yl)pentyl)quinuclidin-1-ium dication.3. A 1 claim 1 ,1′-((3as claim 1 ,6as)-octahydropentalene-2 claim 1 ,5-diyl)bis(1-methylpiperidin-1-ium)dication. This application claims priority to U.S. application Ser. No. 13/649,283, filed on Oct. 11, 2012, and recently allowed, which itself claims the benefit of U.S. Provisional Application No. 61/546,335, filed on Oct. 12, 2011, the entire contents of both of which are hereby incorporated by reference herein.This invention relates to the synthesis of crystalline molecular sieves of the MSE framework-type, such as MCM-68, and to their use in organic conversion processes.MCM-68 is a single crystalline phase molecular sieve material which has a unique 3-dimensional channel structure comprising one 12-membered ring channel system and two 10-membered ring channel systems, in which the channels of each system extend perpendicular to the channels of the other systems and in which the 12-ring channels are generally straight and the 10-ring channels are ...

Подробнее
12-06-2014 дата публикации

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Номер: US20140163066A1
Принадлежит: CHIESI FARMACEUTICI S.p.A.

Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases. 6. A pharmaceutical composition claim 1 , comprising a compound or pharmaceutically acceptable salt according to claim 1 , and one or more pharmaceutically acceptable carriers and/or excipients.7. A method for the prevention and/or treatment of a broncho-obstructive or inflammatory disease claim 1 , comprising administering an effective amount of a compound or pharmaceutically acceptable salt according to to a subject in need thereof.8. A method according to claim 7 , which is for the prevention and/or treatment of a broncho-obstructive disease.9. A method according to claim 8 , wherein said broncho-obstructive or inflammatory disease is asthma chronic bronchitis claim 8 , or chronic obstructive pulmonary disease.10. A combination claim 1 , comprising a compound or pharmaceutically acceptable salt according to one or more active ingredients selected from the group consisting of a beta2-agonist claim 1 , antimuscarinic agent claim 1 , mitogen-activated protein kinase (P38 MAP kinase) inhibitor claim 1 , nuclear factor kappa-B kinase subunit beta (IKK2) inhibitor claim 1 , human neutrophil elastase (HNE) inhibitor claim 1 , phosphodiesterase 4 (PDE4) inhibitor claim 1 , leukotriene modulator claim 1 , non-steroidal anti-inflammatory agent (NSAID) claim 1 , antitussive agent claim 1 , mucus regulator claim 1 , mucolytic claim 1 , expectorant/mucokinetic modulator claim 1 , peptide mucolytic claim 1 , antibiotic claim 1 , inhibitor of JAK claim 1 , SYK inhibitor claim 1 , inhibitor of PI3Kdelta or PI3Kgamma claim 1 , corticosteroid claim 1 , and M3-antagonists/PDE4-inhibitor (MAPI).11. A pharmaceutical composition according to claim 6 , which is in a form suitable to be administered by inhalation.12. A pharmaceutical composition according to claim 11 ...

Подробнее
12-06-2014 дата публикации

Methods of Treatment of Limited Cognitive Impairment

Номер: US20140163067A1
Автор: Koenig Gerhard
Принадлежит: EnVivo Pharmaceuticals, Inc.

A method for improving or treating a Limited Cognitive Impairment (LCI) comprising administering to a subject a compound of the invention, or a pharmaceutically acceptable salt thereof is described together with related compositions. 119-. (canceled)21. The method of claim 20 , wherein the patient has been diagnosed with a symptom claim 20 , condition claim 20 , or disorder classified as Limited Cognitive Impairment.22. The method of claim 20 , wherein the method improves one or more of the following minor impairments: impairment to memory associated with focus and concentration claim 20 , impairment to working memory claim 20 , impairment to cognition claim 20 , impairment to focus claim 20 , impairment to mental quickness claim 20 , and impairment to mental clarity.23. The method of claim 20 , wherein the method improves cognition in the patient.24. The method of claim 20 , wherein the compound of formula (I) is (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide.25. The method of claim 24 , wherein the administered therapeutically effective amount is administered at 0.1 to 3.0 mg/day.26. The method of claim 24 , wherein the administered therapeutically effective amount is administered at 0.03 to 1.0 mg/day.27. The method of claim 24 , wherein the administered therapeutically effective amount is administered at 0.03 to 0.5 mg/day.28. The method of claim 24 , wherein the administered therapeutically effective amount is administered at 0.03 to 0.3 mg/day.29. The method of claim 24 , wherein the administered therapeutically effective amount is administered at 0.03 to 0.1 mg/day. This application claims the benefit of priority from U.S. Provisional Application No. 61/504,154, filed Jul. 1, 2011. The foregoing related application, in its entirety, is incorporated herein by reference.Nicotinic acetylcholine receptors (nAChR) form a family of ion channels activated by acetylcholine. Functional receptors contain five subunits, and there are numerous receptor ...

Подробнее
25-03-2021 дата публикации

PHARMACEUTICAL COMPOSITIONS COMPRISING PYRIDONE DERIVATIVES

Номер: US20210085658A1
Принадлежит:

A pyridone derivative compound and a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof, and a preventive or therapeutic pharmaceutical composition for cognitive disorders that includes the pyridone derivative compound or a pharmaceutically acceptable salt, isomer, solvate or hydrate thereof. 17-. (canceled)9. The method of claim 8 , wherein B is NH.10. The method of claim 8 , wherein A is thiazolyl claim 8 , benzothiazolyl claim 8 , pyridyl claim 8 , isoxazolyl claim 8 , isoquinolinyl claim 8 , quinolyl claim 8 , benzothiadiazolyl claim 8 , thiadiazolyl claim 8 , pyrazolyl or pyrazinyl claim 8 , which is optionally substituted by at least one selected from the group consisting of halo claim 8 , chlorophenyl claim 8 , C-Calkyl claim 8 , C-Ccycloalkyl claim 8 , C-Caralkyl claim 8 , C-Calkoxy claim 8 , and C-Caryl.11. The method of claim 8 , wherein A is thiazolyl or benzothiazolyl optionally substituted by at least one selected from the group consisting of halo claim 8 , chlorophenyl claim 8 , C-Calkyl claim 8 , C-Ccycloalkyl claim 8 , C-Caralkyl claim 8 , C-Calkoxy claim 8 , and C-Caryl.12. The method of claim 8 , wherein A is C-Cheteroaryl substituted by at least one selected from the group consisting of chloro claim 8 , methyl claim 8 , ethyl claim 8 , propyl claim 8 , iso-propyl claim 8 , tert-butyl claim 8 , cyclopentyl claim 8 , phenyl claim 8 , chlorophenyl claim 8 , benzyl claim 8 , cyclohexyl and methoxy.13. The method of claim 8 , wherein A is selected from thiazolyl claim 8 , methylthiazolyl claim 8 , ethylthiazolyl claim 8 , propylthiazolyl claim 8 , iso-propylthiazolyl claim 8 , tert-butylthiazolyl claim 8 , cyclopentylthiazolyl claim 8 , cyclohexylthiazolyl claim 8 , phenylthiazolyl claim 8 , chlorophenylthiazolyl claim 8 , benzylthiazolyl claim 8 , chlorothiazolyl and dimethylthiazolyl.14. The method of claim 13 , wherein B is NH.15. The method of claim 8 , wherein the compound is selected from the group consisting of:N-(1-azabicyclo[ ...

Подробнее
21-03-2019 дата публикации

AZA-BICYCLOALKYL ETHERS AND THEIR USE AS ALPHA7-NACHR AGONISTS

Номер: US20190083474A1
Принадлежит:

The present invention relates to 1-aza-bicycloalkyl derivatives of formula I, 1. A method for the prevention or treatment of a disease or disorder in a subject in need of such treatment , the method comprising:administering to the subject a therapeutically effective amount of a selective α7 nicotinic acetylcholine receptor (nAChR) agonist,wherein the selective α7 nAChR agonist is (R)-3-(6-p-tolyl-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in free base form or in acid addition salt form.2. The method of claim 1 , wherein the disease or disorder is a psychotic disorder.3. The method of claim 2 , wherein the psychotic disorder is selected from the group consisting of: mania claim 2 , depression claim 2 , and anxiety.4. The method of claim 1 , wherein the disease or disorder is a neurodegenerative disorder.5. The method of claim 4 , wherein the neurodegenerative disorder is selected from the group consisting of: senile dementia claim 4 , Alzheimer's disease claim 4 , and an intellectual impairment disorder.6. The method of claim 1 , wherein the disease or disorder is attention deficit hyperactivity disorder (ADHD) claim 1 , Parkinson's Disease claim 1 , Huntington's chorea claim 1 , amyotrophic lateral sclerosis claim 1 , multiple sclerosis claim 1 , epilepsy claim 1 , convulsions claim 1 , Tourette syndrome claim 1 , obsessive compulsive disorder (OCD) claim 1 , memory deficits and dysfunction claim 1 , a learning deficit claim 1 , a panic disorder claim 1 , narcolepsy claim 1 , nociception claim 1 , AIDS dementia claim 1 , autism claim 1 , tardive dyskinesia claim 1 , social phobia claim 1 , or pseudodementia.7. The method of claim 1 , wherein the disease or disorder is neuropathic pain claim 1 , postoperative pain claim 1 , inflammatory pain claim 1 , or phantom limb pain.8. A method for improving cognition in a subject in need of such treatment claim 1 , the method comprising:administering to the subject a therapeutically effective amount of a selective α7 ...

Подробнее
19-06-2014 дата публикации

1,7-DIAZACARBAZOLES AND METHODS OF USE

Номер: US20140171407A1
Принадлежит: Genentech, Inc.

The invention relates to 1,7-diazacarbazole compounds of Formula (I), (I-a) and (I-b) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. 4. The compound of wherein Ris H claim 3 , CHor halo.5. The compound of wherein Ris —NRRor —OR claim 4 , wherein Rand Rare optionally taken together with the attached N atom to form a 4-7 membered ring having additional 0-2 heteroatoms selected from O claim 4 , S claim 4 , and N claim 4 , said ring being optionally substituted with one to four Rgroups.7. The compound of wherein Ris —NRRor —OR claim 1 , wherein Rand Rare optionally taken together with the attached N atom to form a 4-7 membered ring having additional 0-2 heteroatoms selected from O claim 1 , S claim 1 , and N claim 1 , said ring being optionally substituted with one to four Rgroups.9. The compound of wherein Ris H claim 1 , CN or pyrrolyl optionally substituted with C-Calkyl.10. The compound of wherein Ris H claim 1 , CN claim 1 , N-methylpyrrolyl claim 1 , or pyrrolyl.11. The compound of wherein Ris H or CN.12. The compound of wherein Ris CN.13. A compound selected from the group consisting of:4-(N-(morpholin-2-ylmethyl))-9H-dipyrido[2,3-b;4′,3′-d]pyrrole-6-carbonitrile;4-(azetidin-3-ylmethoxy)-9H-dipyrido[2,3-b;4′,3′-d]pyrrole-6-carbonitrile;(R)-4-(morpholin-2-ylmethoxy)-9H-dipyrido[2,3-b;4′,3′-d]pyrrole-6-carbonitrile;(S)-4-(morpholin-2-ylmethoxy)-9H-dipyrido[2,3-b;4′,3′-d]pyrrole-6-carbonitrile;(R)-4-(quinuclidin-3-yloxy)-9H-dipyrido[2,3-b;4′,3′-d]pyrrole-6-carbonitrile;4-((1s,3s)-cyclobutanamine-3-yloxy)-9H ...

Подробнее
19-06-2014 дата публикации

NOVEL COMPOUNDS

Номер: US20140171414A1
Принадлежит: CHIESI FARMACEUTICI S.p.A.

Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for treating diseases and conditions in which HNE is implicated. 2. A compound or pharmaceutically acceptable salt according to claim 1 , wherein A is CH claim 1 , B is CH claim 1 , and D is CH.3. A compound or pharmaceutically acceptable salt according to claim 1 , wherein Ris —[CH]-G-[CH]—CH—NRRR.4. A compound or pharmaceutically acceptable salt according to claim 1 , wherein Ris —C(O)—XR.5. A compound or pharmaceutically acceptable salt according to claim 1 , wherein X is —O— and Ris (C-C)alkyl.6. A compound or pharmaceutically acceptable salt according to claim 1 , wherein Ris hydrogen or —(CH)SO(C-C)alkyl.7. A compound or pharmaceutically acceptable salt according to claim 1 , which is a compound selected from the group consisting of:5-[4-cyano-2-(4-hydroxy-but-1-ynyl)-phenyl]-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylic acid methyl ester;5-[4-cyano-2-(3-dimethylamino-prop-1-ynyl)-phenyl]-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylic acid methyl ester;5-[4-cyano-2-(3-dimethylamino-prop-1-ynyl)-phenyl]-2-(3-methanesulfonyl-propyl)-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylic acid methyl ester;(3-{5-cyano-2-[2-(3-methanesulfonyl-propyl)-6-methoxycarbonyl-7-methyl-3-oxo-8-m-tolyl-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidin-5-yl]-phenyl}-prop-2-ynyl)-trimethyl-ammonium formate;5-[4-cyano-2-(3-dimethylamino-propyl)-phenyl]-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylic acid methyl ester;5-(4-cyano-2-dimethylaminomethyl-phenyl)-7-methyl-3-oxo-8-(3-trifluoromethyl-phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-6-carboxylic acid methyl ester;{5-cyano-2-[6-methoxycarbonyl-7-methyl-3-oxo-8-(3- ...

Подробнее
19-06-2014 дата публикации

AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE

Номер: US20140171646A1
Принадлежит: Helsinn Healthcare S.A.

Amorphous and polymorphic of palonosetron hydrochloride are disclosed that can be characterized by X-ray powder diffraction patterns, thermal properties, purity and methods of manufacture. These forms of palonosetron hydrochloride can be produced from solution or by solid state interconversions. The forms can be used in pharmaceutical formulations: particularly preferred uses of these formulations are in prevention and treatment of nausea and emesis arising from chemotherapy or postoperative side effects. The forms can optionally be used as mixtures of the crystalline and/or amorphous forms. 135-. (canceled)36. Amorphous palonosetron hydrochloride.3738-. (canceled) The present application claims priority to U.S. Provisional Application No. 60/873,656, filed Dec. 7, 2006 (abandoned by operation of law). The contents of said application are incorporated by reference as if fully set forth herein.The present invention relates to crystalline and amorphous forms of palonosetron hydrochloride, mixtures thereof, pharmaceutical compositions thereof, and uses for such forms and compositions.The nausea and emetogenic side effects of anti-cancer chemotherapy and radiotherapy are a widespread and longstanding problem. Perhaps less well known but no less important are post-operative nausea and emesis, which may have physiological mechanisms related to the effects seen for chemotherapy. Palonosetron hydrochloride has recently emerged as a highly efficacious anti-nauseant and anti-emetic for use with emetogenic anti-cancer chemotherapies. (Macciocchi, A., et al., “A Phase II dose-ranging study to assesses single intravenous doses of palonosetron for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting,” 2002; Abstract 1480. Palonosetron also prevents postoperative nausea and vomiting. (Chelly, J., et al., “Oral RS-25259 prevents postoperative nausea and vomiting following laparoscopic surgery,” 85(Suppl. 21):abstract no. 2A (1996)).Palonosetron is selective, ...

Подробнее
08-04-2021 дата публикации

PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6-(3-METHYL-1H-PYRAZOL-4-YL)THIENO[3,2-d]PYRIMIDIN-4(3H)-ONE

Номер: US20210101897A1
Принадлежит:

The present invention provides processes and synthetic intermediates for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4 (3H)-one or a salt, hydrate, or tautomer thereof, or any combination thereof, which are Cdc7 kinase inhibitors, and are useful for the treatment of disorders of cell proliferation, particularly cancer, and other disorders associated with Cdc7 activity. 2. The process according to claim 1 , wherein the converting of the chiral center of 2-(1-azabicyclo[2.2.2]oct-2-yl)-6-(3-methyl-1H-pyrazol-4-yl)thieno[3 claim 1 ,2-d]pyrimidin-4(3H)-one as the Compound (VIII) claim 1 , or salt claim 1 , hydrate claim 1 , or tautomer thereof claim 1 , or combination thereof comprises treating the 2-(1-azabicyclo[2.2.2]oct-2-yl)-6-(3-methyl-1H-pyrazol-4-yl)thieno[3 claim 1 ,2-d]pyrimidin-4(3H)-one as the Compound (VIII) claim 1 , or salt claim 1 , hydrate claim 1 , or tautomer thereof claim 1 , or combination thereof claim 1 , with a chiral acid in the presence of a dynamic resolution promoter to produce a chiral acid salt of the 2-[(2S)-1-azabicyclo[2.2.2] oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3 claim 1 ,2-d] pyrimidin-4 (3H)-one.7. The process according to claim 2 , wherein the dynamic resolution promoter comprises formic acid claim 2 , acetic acid claim 2 , propionic acid claim 2 , trifluoroacetic acid claim 2 , benzoic acid claim 2 , triethylamine claim 2 , 1 claim 2 ,4-diazabicyclo[2.2.2]octane claim 2 , or diazabicycloundecene.8. The process according to claim 2 , wherein the dynamic resolution promoter comprises acetic acid.9. The process according to claim 2 , wherein the treating of the 2-(1-azabicyclo[2.2.2]oct-2-yl)-6-(3-methyl-1H-pyrazol-4-yl)thieno[3 claim 2 ,2-d]pyrimidin-4(3H)-one as the Compound (VIII) claim 2 , or salt claim 2 , hydrate claim 2 , or tautomer thereof claim 2 , or combination thereof with the chiral acid in the presence of the dynamic resolution promoter is performed in ...

Подробнее
23-04-2015 дата публикации

PROCESS OF PREPARING SOLIFENACIN OR SALT THEREOF, AND NOVEL INTERMEDIATE USED IN THE PROCESS

Номер: US20150112072A1
Принадлежит: Kyung Dong Pharm. Co., Ltd.

Disclosed herein is a method of preparing solifenacin or a salt thereof, including the steps of: (a) reacting (R)-quinuclidinol with bis(pentafluorophenyl)carbonate in an organic solvent to prepare a solifenacin intermediate, (3R)-1-azabicyclo[2,2,2]oct-3-yl pentafluorophenylcarbonate, and (b) reacting the solifenacin intermediate with (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline in an organic solvent to prepare solifenacin. The method is advantageous in that high-purity solifenacin or a salt thereof can be simply and efficiently prepared with high yield using a novel intermediate. 3. The method of claim 1 , wherein claim 1 , in the step (a) claim 1 , an amount of 1 to 3 molar equivalents of bis(pentafluorophenyl)carbonate of Formula (VII) per 1 molar equivalent of (R)-quinuclidinol of Formula (VI) is used.4. The method of claim 1 , wherein claim 1 , in the step (a) or (b) claim 1 , the reaction is performed at a temperature of 10° C. to 30° C.5. The method of claim 4 , wherein claim 4 , in the step (a) or (b) claim 4 , the reaction is performed for 2 hours to 12 hours.6. The method of claim 1 , wherein claim 1 , in the step (a) or (b) claim 1 , the reaction is performed without using a base.7. The method of claim 1 , wherein claim 1 , in the step (a) or (b) claim 1 , the organic solvent is selected from the group consisting of toluene claim 1 , ethyl acetate claim 1 , dichloromethane claim 1 , acetone claim 1 , isopropanol and mixtures thereof.8. The method of claim 1 , wherein the step (b) is performed by an in-situ reaction in which the (1S)-1-phenyl-1 claim 1 ,2 claim 1 ,3 claim 1 ,4-tetrahydroisoquinoline of Formula (V) is added dropwise without dissociating the (3R)-1-azabicyclo[2 claim 1 ,2 claim 1 ,2]oct-3-yl pentafluorophenylcarbonate of Formula (IV) prepared in the step (a).9. The method of claim 2 , wherein the step (c) is performed in the presence of an organic solvent selected from the group consisting of aliphatic alcohol claim 2 , ketone claim 2 , ...

Подробнее
19-04-2018 дата публикации

Process for the Preparation of Aclidinium Bromide

Номер: US20180105517A1
Принадлежит:

A process for preparing (3R)-3-[2-Hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide) comprises reacting 2-hydroxy-2,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R)yl methyl ester and 3-phenoxypropyl bromide, wherein the reaction takes place in a solvent or mixture of solvents selected from the group of amides and/or the group of solvents with a sulfoxide group. Also provided is a crystalline aclidinium bromide characterized by a powder XRPD pattern having peaks at 7.7±0.2° 2θ, 10.4±0.2° 2θ, 13.2±0.2° 2θ, 13.8±0.2° 2θ, 19.9±0.2° 2θ, 20.3±0.2° 2θ, 20.8±0.2° 2θ, 24.2±0.2° 2θ, 25.7±0.2° 2θ, 26.1±0.2° 2θ, 29.2±0.2° 2θ, 30.8±0.2° 2θ. A pharmaceutical composition comprises aclidinium bromide according to the invention and a pharmaceutically acceptable excipient. 1. A process for preparing (3R)-3-[2-Hydroxy(di-2-thienyl)acetoxy]-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide) by reacting 2-hydroxy-2 ,2-dithien-2-ylacetic acid 1-azabicyclo[2.2.2]oct-3(R) yl methyl ester and 3-phenoxypropyl bromide , wherein the reaction takes place in a solvent or mixture of solvents selected from the group of amides and/or the group of solvents with a sulfoxide group.2. The process according to wherein the reaction temperature is below 100° C. claim 1 , preferably below 50° C.3. The process according to wherein the reaction temperature is from about 30° C. to about 20° C. claim 1 , preferably about 30° C.4. The process according to wherein the reaction temperature is about 20° C.5. The process according to wherein the reaction takes place under a flow of an inert gas claim 1 , preferentially under a flow of a dry inert gas claim 1 , preferably under a flow of dry nitrogen claim 1 , dry helium or a mixture thereof.6. The process according to wherein the reaction takes place at a pressure below the atmospheric pressure.7. The process according to wherein the alcohol formed is removed from the reaction ...

Подробнее
02-04-2020 дата публикации

PROCESS FOR THE PREPARATION OF A NOVEL UMECLIDINIUM SYNTHESIS INTERMEDIATE

Номер: US20200102300A1
Принадлежит:

The present invention relates to a process for the preparation of a novel and versatile synthesis intermediate and its use in the preparation of umeclidinium. The invention also relates to some reference standards allowing to detect impurity traces recurring in the preparation of umeclidinium and a process for their preparation. 2. The process according to claim 1 , wherein characterized in that said solvent is selected from aprotic solvents.3. The process according to claim 1 , wherein phenyl lithium is used at a rate of 1.2-1.3 moles per mole of compound of formula (II).5. The process according to claim 1 , wherein said compound of formula (II) is obtained reacting the Weinreb amide of quinuclidine with phenyl lithium or phenyl magnesium bromide.7. Method of preparing the compound of formula (I) and/or umeclidinium with the compound of formula (II) and/or the compound of formula (III) as intermediates.812.-. (canceled)13. The process according to claim 1 , wherein said solvent is selected from aprotic solvents and mixtures thereof.14. The process according to claim 1 , wherein said solvent is selected from the group consisting of ethers claim 1 , aliphatic hydrocarbons claim 1 , aromatic hydrocarbons and mixtures thereof.15. The process according to claim 1 , wherein said solvent is selected from the group consisting of tetrahydrofuran (THF) claim 1 , methyl-tert-butyl ether (MTBE) claim 1 , toluene and mixtures thereof.16. The process according to claim 1 , comprising reacting said compound of formula (II) with phenyl lithium.17. The process according to claim 1 , wherein said phenyl lithium is added in stoichiometric amount or in slight excess with respect to the compound of formula (II).18. The process according to claim 4 , wherein said leaving group is selected from halogen claim 4 , tosyl claim 4 , mesyl and triflate.19. The compound according to claim 6 , wherein said salts is selected from hydrochloride claim 6 , hydrobromide claim 6 , sulphate and ...

Подробнее
26-04-2018 дата публикации

POLYCATIONIC AMPHIPHILES AND POLYMERS THEREOF AS ANTIMICROBIAL AGENTS AND METHODS USING SAME

Номер: US20180111893A1
Принадлежит:

The present invention includes novel polycationic amphiphilic compounds useful as antimicrobial agents. The present invention further includes novel polymers of polycationic amphiphilic compounds useful as antimicrobial agents. The present invention further includes methods useful for removing microorganisms and/or biofilm-embedded microorganisms from a surface. The present invention further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms and/or biofilm-embedded microorganisms on a surface. 2. The compound of claim 1 , wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Ris Calkyl claim 1 , Calkyl claim 1 , or benzyl.34.-. (canceled)5. The compound of claim 1 , wherein at least one of X claim 1 , X claim 1 , X claim 1 , X claim 1 , and Xis selected from the group consisting of Calkyl claim 1 , Calkyl claim 1 , C-Calkyl-OC(O)O—C-Calkyl claim 1 , C-Calkyl-NC(O)O—C-Calkyl claim 1 , C-Calkyl-S—C-Calkyl claim 1 , C-Calkyl-NC(S)N—C-Calkyl claim 1 , and C-Calkyl-NC(O)N—C-Calkyl claim 1 , wherein the alkyl group may be optionally substituted.69.-. (canceled)1112.-. (canceled)1415.-. (canceled)1921.-. (canceled)24. (canceled)2628.-. (canceled)3034.-. (canceled)36. The method of claim 35 , wherein the composition further comprises a base material.37. (canceled)38. The method of claim 35 , wherein the composition is contacted with the at least one surface for a period of time sufficient to form a coating of the composition on the at least one surface.3949.-. (canceled)51. (canceled)52. The polymer of claim 51 , wherein the polymerizable moiety is selected from the group consisting of styrene claim 51 , methacrylate claim 51 , methyl methacrylate claim 51 , methylacrylamide claim 51 , substituted methylacrylamide claim 51 , acrylamide claim 51 , and carbonate.5355.-. (canceled)56. ...

Подробнее
05-05-2016 дата публикации

2-HETEROARYL CARBOXAMIDES

Номер: US20160122337A1
Принадлежит:

The invention relates to novel 2-heteroaryl carboxamides and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory. 2. Compounds according to claim 1 , of the formula (I) claim 1 , in which{'sup': '1', 'Ris 1-azabicyclo[2.2.2]oct-3-yl,'}{'sup': '2', 'sub': 1', '4, 'Ris hydrogen or C-C-alkyl,'}{'sup': '3', 'sub': 1', '4, 'Ris hydrogen, fluorine, chlorine, bromine or C-C-alkyl,'}{'sup': '4', 'sub': 1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '3', '6', '3', '6', '1', '4, 'claim-text': {'sub': 1', '4', '1', '4', '1', '4, 'claim-text': [{'sub': 1', '4', '1', '4', '1', '4, 'C-C-alkylaminocarbonyl may optionally be substituted by C-C-alkoxy or C-C-alkylamino,'}, {'sub': 1', '4', '1', '4, 'C-C-alkylcarbonylamino may optionally be substituted by C-C-alkoxy, and, heterocyclyl may optionally be substituted by oxo,'}], 'where C-C-alkyl may optionally be substituted by hydroxyl, cyano, amino, C-C-alkylaminocarbonylamino, C-C-alkylaminocarboxyl, heterocyclyl or aryl,'}, 'Ris hydrogen, fluorine, chlorine, bromine, cyano, amino, trifluoromethyl, trifluoromethoxy, C-C-alkyl, C-C-alkylcarbonyl, C-C-alkylamino, formyl, hydroxycarbonyl, C-C-alkoxy, C-C-alkoxycarbonyl, C-C-alkylthio, C-C-alkylcarbonylamino, C-C-alkylaminocarbonyl, C-C-alkylsulphonylamino, C-C-cycloalkylcarbonylamino, C-C-cycloalkylaminocarbonyl, pyrrolyl, C-C-alkylaminocarbonylamino, heterocyclylcarbonyl, heterocyclylcarbonylamino, heteroarylcarbonylamino, hydroxyl, phenyl or heterocyclyl,'}A is oxygen or sulphur;{'sub': 1', '4, 'the ring B is benzo or pyrido, each of which are optionally substituted by radicals from the series halogen, cyano, trifluoromethyl, trifluoromethoxy and C-C-alkyl,'}and{'sub': 1', '4', '1', '4, 'E is C≡C, arylene and heteroarylene, where arylene and heteroarylene may be substituted by radicals from the series halogen, cyano, trifluoromethyl, ...

Подробнее
03-05-2018 дата публикации

NON-DELIQUESCENT ACID ADDITION SALT OF 3-AMINOQUINUCLIDINE

Номер: US20180118736A1
Принадлежит: YUKI GOSEI KOGYO CO. LTD.

A novel acid addition salt of 3-aminoquinuclidine, which is an industrially useful compound as an intermediate of medicines and does not exhibit deliquescence, is provided. 1. An acid addition salt of 3-aminoquinuclidine selected from the group consisting of racemic 3-aminoquinuclidine , (R)-3-aminoquinuclidine , and (S)-3-aminoquinuclidine , and acid selected from the group consisting of phosphoric acid , sulfuric acid , fumaric acid , terephthalic acid , oxalic acid , p-toluenesulfonic acid , (±)-10-camphorsulfonic acid , and (−)-10-camphorsulfonic acid , wherein the acid addition salt does not exhibit deliquescence.2. The acid addition salt according to claim 1 , of racemic 3-aminoquinuclidine and acid selected from the group consisting of phosphoric acid claim 1 , fumaric acid claim 1 , terephthalic acid claim 1 , oxalic acid claim 1 , p-toluenesulfonic acid claim 1 , and (±)-10-camphorsulfonic acid claim 1 , wherein the acid addition salt does not exhibit deliquescence.3. The acid addition salt according to claim 1 , selected from the group consisting of[1] racemic 3-aminoquinuclidine.sesquiphosphate,[2] racemic 3-aminoquinuclidine.monofumarate,[3] racemic 3-aminoquinuclidine.monoterephthalate,[4] racemic 3-aminoquinuclidine.monooxalate,[5] racemic 3-aminoquinuclidine.mono-p-toluenesulfonate, and[6] racemic 3-aminoquinuclidine.mono-(±)-10-camphorsulfonate.4. The acid addition salt according to claim 1 , of (R)-3-aminoquinuclidine and acid selected from the group consisting of phosphoric acid claim 1 , sulfuric acid claim 1 , fumaric acid claim 1 , terephthalic acid claim 1 , oxalic acid claim 1 , p-toluenesulfonic acid claim 1 , and (−)-10-camphorsulfonic acid claim 1 , wherein the acid addition salt does not exhibit deliquescence.5. The acid addition salt according to claim 1 , selected from the group consisting of[1] (R)-3-aminoquinuclidine sesquiphosphate,[2] (R)-3-aminoquinuclidine.monosulfate,[3] (R)-3-aminoquinuclidine.monofumarate,[4] (R)-3- ...

Подробнее
16-04-2020 дата публикации

COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA

Номер: US20200115377A1
Автор: Horn Gerald
Принадлежит:

The invention provides compositions and methods for the treatment of presbyopia. The methods preferably comprise storing an aceclidine composition in a container having a headspace at a temperature from about 2 to about 8 degrees Celsius. The methods further comprise filling the container under an inert gas overlay and/or enclosing the container an anti-leaching material or disposing the container in a second container containing an anti-leaching material. 1. A method of stabilizing a composition comprising aceclidine comprising storing the composition in a container having a headspace at a temperature from about 2 degrees Celsius to about 8 degrees Celsius.2. The method of claim 1 , wherein the composition is filled into the container under an inert gas overlay.3. The method of claim 2 , wherein the headspace is purged with an inert gas.4. The method of claim 1 , wherein the container comprises a closure and a vessel wherein a portion of the closure and a portion of the vessel are sealed with an anti-leaching material selected from the group consisting of biaxially-oriented polyethylene terephthalate claim 1 , polytetrafluorethylene and aluminum foil.5. The method of claim 1 , wherein the container is disposed in a second container that is formed with or lined with an anti-leaching material selected from the group consisting of biaxially-oriented polyethylene terephthalate claim 1 , polytetrafluorethylene and aluminum foil.6. The method of claim 1 , wherein aceclidine is at a concentration from about 0.25% to about 4.0% w/v aceclidine claim 1 , wherein w/v denotes weight by total volume of the composition.7. The method of claim 1 , wherein the method provides at least 90% stability of aceclidine for at least 7 months.8. The method of claim 5 , wherein the method provides at least 90% stability of aceclidine for at least 12 months.9. The method of claim 1 , wherein the composition further comprises a viscosity agent claim 1 , a polysorbate claim 1 , a cryoprotectant ...

Подробнее
14-05-2015 дата публикации

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Номер: US20150133491A1
Автор: Linney Ian, RANCATI Fabio
Принадлежит: CHIESI FARMACEUTICI S.p.A.

Compounds of formula (I) described herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases. 6. A pharmaceutical composition claim 1 , comprising a compound or pharmaceutically acceptable salt according to and one or more pharmaceutically acceptable carriers and/or excipients.7. A method for the prevention and/or treatment of a broncho-obstructive or inflammatory disease claim 1 , comprising administering an effective amount of a compound or pharmaceutically acceptable salt according to to a subject in need thereof.8. A method according to claim 7 , wherein said broncho-obstructive or inflammatory disease is asthma claim 7 , chronic bronchitis claim 7 , or chronic obstructive pulmonary disease.9. A combination claim 1 , comprising a compound or pharmaceutically acceptable salt according to and one or more active ingredients selected from the group consisting of a beta2-agonist claim 1 , antimuscarinic agent claim 1 , mitogen-activated protein kinase (P38 MAP kinase) inhibitor claim 1 , nuclear factor kappa-B kinase subunit beta (IKK2) inhibitor claim 1 , human neutrophil elastase (HNE) inhibitor claim 1 , phosphodiesterase 4 (PDE4) inhibitor claim 1 , leukotriene modulator claim 1 , non-steroidal anti-inflammatory agent (NSAID) claim 1 , antitussive agent claim 1 , mucus regulator claim 1 , mucolytic claim 1 , expectorant/mucokinetic modulator claim 1 , peptide mucolytic claim 1 , antibiotic claim 1 , inhibitor of JAK claim 1 , SYK inhibitor claim 1 , inhibitor of PI3Kdelta or PI3Kgamma claim 1 , corticosteroid claim 1 , and M3-antagonist/PDE4-inhibitor (MAPI).10. A pharmaceutical composition according to claim 6 , which is in a form suitable to be administered by inhalation.11. A pharmaceutical composition according to claim 6 , which is an inhalable powder claim 6 , a propellant-containing metering aerosol claim 6 , or a propellant- ...

Подробнее
14-05-2015 дата публикации

METHODS AND COMPOSITIONS FOR PREPARING NORIBOGAINE FROM VOACANGINE

Номер: US20150133655A1
Принадлежит: DEMERX, INC.

Disclosed are methods and compositions for preparing and purifying the non-addictive alkaloid noribogaine. 1. A method for preparing and purifying noribogaine which method comprises:a) converting voacangine to 12-hydroxyibogamine-18-carboxylic acid or the carboxylic acid salt or ester thereof, wherein the indole nitrogen is optionally protected by an amino protecting group;b) optionally isolating the 12-hydroxyibogamine-18-carboxylic acid or the carboxylic acid salt, ester and/or amino protected derivative thereof;c) converting the product of step a) or b) to noribogaine; andd) isolating noribogaine.2. The method of claim 1 , wherein b) and c) are conducted in a one-pot synthesis.3. The method of claim 1 , wherein step b) further comprises the steps of b′) de-esterifying the 12-hydroxyibogamine-18-carboxylic acid methyl ester to provide 12-hydroxyibogamine-18-carboxylic acid claim 1 , and b″) decarboxylating the 12-hydroxyibogamine-18-carboxylic acid to provide the noribogaine.4. A method for preparing and purifying noribogaine which method comprises:a) converting voacangine to 12-hydroxyibogamine-18-carboxylic acid wherein the indole nitrogen is optionally protected by an amino protecting group;b) converting the 12-hydroxyibogamine-18-carboxylic acid to noribogaine; andc) isolating noribogaine.5. A method for preparing and purifying noribogaine which method comprises:a) converting voacangine to 12-hydroxyibogamine-18-carboxylic acid methyl ester wherein the indole nitrogen is optionally protected by an amino protecting group;b) optionally covalently attaching 12-hydroxyibogamine-18-carboxylic acid methyl ester or amino protected derivative thereof to a solid support via the hydroxyl group of 12-hydroxyibogamine-18-carboxylic acid methyl ester or amino protected derivative thereof so as to form a suspension of solid supports having 12-hydroxyibogamine-18-carboxylic acid methyl ester or amino protected derivative thereof bound thereto;c) removing residual voacangine ...

Подробнее
10-05-2018 дата публикации

AZABICYCLIC CARBAMATES AND THEIR USE AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS

Номер: US20180127409A1
Принадлежит:

The invention relates to novel benzothiophene-, benzofuran-, and indole ureas and to the use thereof for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning, and/or memory. 115-. (canceled) The invention relates to novel benzothiophene-, benzofuran- and indoleureas, processes for their preparation, and their use for producing medicaments for the treatment and/or prophylaxis of diseases and for improving perception, concentration, learning and/or memory.Nicotinic acetylcholine receptors (nAChR) form a large family of ion channels which are activated by the messenger acetylcholine which is produced in the body (Galzi et al., 1995, 34, 563-582). A functional nAChR consists of five subunits which may be different (certain combinations of α1-9 and (β1-4,γ,δ,ε subunits) or identical (α 7-9). This leads˜to the formation of a diversity of subtypes which differ in the distribution in the muscles, the nervous system and other organs (McGehee et al., 1925, 57, 521-546). Activation of nAChR leads to influx of cations into the cell and to stimulation of nerve cells or muscle cells. Selective activation of individual nAChR subtypes restricts this stimulation to the cell types which have a corresponding subtype and is thus able to avoid unwanted side effects such as, for example, stimulation of nAChR in the muscles. Clinical experiments with nicotine and experiments in various animal models indicate that central nicotinic acetylcholine receptors are involved in learning and memory processes (e.g. Rezvani et al., 2001, 49, 258-267).Nicotinic acetylcholine receptors of the alpha7 subtype (α7 nAChR) have a particularly high concentration in regions of the brain which are important for learning and memory, such as the hippocampus and the cerebral cortex (Séguéla et al., 1993, 13, 596-604). The α7 nAChR has a particularly high permeability for calcium ions, increases glutamatergic neuotransmission influences the ...

Подробнее
21-05-2015 дата публикации

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

Номер: US20150139916A1
Принадлежит: CHIESI FARMACEUTICI S.p.A.

Compounds of formula (I) defined herein act both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists and are useful for the prevention and/or treatment of broncho-obstructive or inflammatory diseases. 6. A pharmaceutical composition claim 1 , comprising a compound or pharmaceutically acceptable salt according to claim 1 , and one or more pharmaceutically acceptable carriers and/or excipients.7. A method for the prevention and/or treatment of a broncho-obstructive or inflammatory disease claim 1 , comprising administering an effective amount of a compound or pharmaceutically acceptable salt according to to a subject in need thereof.8. A method according to claim 7 , which is for the prevention and/or treatment of a broncho-obstructive disease.9. A method according to claim 8 , wherein said broncho-obstructive or inflammatory disease is asthma chronic bronchitis claim 8 , or chronic obstructive pulmonary disease.10. A combination claim 1 , comprising a compound or pharmaceutically acceptable salt according to one or more active ingredients selected from the group consisting of a beta2-agonist claim 1 , antimuscarinic agent claim 1 , mitogen-activated protein kinase (P38 MAP kinase) inhibitor claim 1 , nuclear factor kappa-B kinase subunit beta (IKK2) inhibitor claim 1 , human neutrophil elastase (HNE) inhibitor claim 1 , phosphodiesterase 4 (PDE4) inhibitor claim 1 , leukotriene modulator claim 1 , non-steroidal anti-inflammatory agent (NSAID) claim 1 , antitussive agent claim 1 , mucus regulator claim 1 , mucolytic claim 1 , expectorant/mucokinetic modulator claim 1 , peptide mucolytic claim 1 , antibiotic claim 1 , inhibitor of JAK claim 1 , SYK inhibitor claim 1 , inhibitor of PI3Kdelta or PI3Kgamma claim 1 , corticosteroid claim 1 , and M3-antagonists/PDE4-inhibitor (MAPI).11. A pharmaceutical composition according to claim 6 , which is in a form suitable to be administered by inhalation.12. A pharmaceutical composition according to claim 11 ...

Подробнее
17-05-2018 дата публикации

Aminobenzisoxazole Compounds as Agonists of Alpha7-Nicotinic Acetylcholine Receptors

Номер: US20180134696A1
Принадлежит:

The present invention relates to novel aminobenzisoxazole compounds, and pharmaceutical compositions of the same, that are suitable as agonists or partial agonists of Alpha7-nAChR, and methods of preparing these compounds and compositions, and the use of these compounds and compositions in methods of maintaining, treating and/or improving cognitive function. In particular, methods of administering the compound or composition to a patient in need thereof, for example a patient with a cognitive deficiency and/or a desire to enhance cognitive function, that may derive a benefit therefrom. 2. The compound of claim 1 , wherein Rindependently represents —H claim 1 , -D claim 1 , or halogen radical.370-. (canceled)71. The compound of claim 1 , where Rindependently represents —H claim 1 , -D claim 1 , or halogen radical.72. The compound of claim 1 , wherein Rindependently represents —H claim 1 , -D claim 1 , —F claim 1 , —Cl claim 1 , —Br claim 1 , —CN claim 1 , an unbranched C-C-alkyl radical claim 1 , a branched C-C-alkyl radical claim 1 , a C-C-cycloalkyl radical claim 1 , an unbranched —OC-C-alkyl claim 1 , a branched or cyclic —OC-C-alkyl claim 1 , —N(R)(R) claim 1 , —(CO)N(R)(R) claim 1 , —NR(CO)(R) claim 1 , —SOC-C-alkyl claim 1 , —SON(R)(R) claim 1 , —(CH)SOC-C-alkyl claim 1 , —(CH)SON(R)(R) claim 1 , —N(R)SOC-C-alkyl claim 1 , an aryl radical claim 1 , or a heteroaryl radical; wherein the alkyl portion of the unbranched C-C-alkyl radical claim 1 , the branched C-C-alkyl radical claim 1 , the C-C-cycloalkyl radical claim 1 , the unbranched —OC-C-alkyl claim 1 , the branched or cyclic —OC-C-alkyl claim 1 , the —SOC-C-alkyl claim 1 , the —(CH)SOC-C-alkyl claim 1 , or the —N(R)SOC-C-alkyl claim 1 , may be independently substituted with up to 5 radical substituents comprising: -D claim 1 , —F claim 1 , —Cl claim 1 , —Br claim 1 , ═O claim 1 , —OR claim 1 , —(CH)OR claim 1 , —N(R)(R) claim 1 , —NR(CO)(R) claim 1 , —(CH)N(R)(R) claim 1 , —SOC-C-alkyl claim 1 , —SON(R)(R) ...

Подробнее
07-08-2014 дата публикации

SALTS OF AZA-BICYCLIC DI-ARYL ETHERS AND METHODS TO MAKE THEM OR THEIR PRECURSORS

Номер: US20140220125A1
Принадлежит: NOVARTIS AG

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments. 1. A salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane wherein said salt is the fumarate , maleate , chloride , phosphate , succinate or malonate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane.2. The salt according to claim 1 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form.3. The salt according to claim 2 , wherein the salt is characterized by an XRPD pattern substantially the same as the XRPD pattern shown in .4. The salt according to claim 1 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form claim 1 , wherein the mean particle size of the crystals is at least 15 μm.5. The salt according to claim 2 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form claim 2 , and wherein the salt is in substantially pure form.6. The salt according to claim 2 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form claim 2 , and wherein the salt has a purity greater than 90 weight %.7. A pharmaceutical composition claim 1 , which comprises a salt as defined in as active ingredient and at least one pharmaceutically acceptable carrier.8. A pharmaceutical composition claim 1 , which comprises a salt as defined in in combination with one or more further therapeutic agent as active ingredients and at least one pharmaceutically acceptable carrier.9. A pharmaceutical composition comprising mono-fumarate of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza- ...

Подробнее
09-05-2019 дата публикации

PROCESS FOR THE PREPARATION OF ISOXAZOLINE COMPOUNDS

Номер: US20190133129A1
Принадлежит: MERIAL INC.

This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine-based chiral phase transfer catalyst. The invention also relates to novel quinine-based phase transfer catalysts and to a toluene solvent form of the isoxazoline compound of the invention. 138-. (canceled)42. The crystalline toluene solvate of characterized by an X-ray powder diffraction pattern substantially as shown in .43. The crystalline toluene solvate of which is characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm at a temperature of about 83° C. to about 87° C. claim 39 , corresponding to the toluene solvate.44. The crystalline toluene solvate of which is characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm at a temperature of about 84.7° C. claim 39 , corresponding to the toluene solvate.45. The crystalline toluene solvate of claim 39 , which is characterized by a differential scanning calorimetry thermogram substantially as shown in .46. The crystalline toluene solvate of characterized by a thermogravimetric analysis (TGA) thermogram characterized by weight loss of about 10.5% from about about 26° C. at about 160° C.47. The crystalline toluene solvate of characterized by thermogravimetric analysis thermogram substantially as shown in .51. The crystalline toluene solvate of claim 39 , wherein the molar ratio of (S)-afoxolaner to toluene is about 1:1.52. The crystalline toluene solvate of claim 39 , wherein the crystalline (S)-afoxolaner toluene solvate is isolated.53. The crystalline toluene solvate of claim 39 , wherein at least 90% of (S)-afoxolaner by weight is a crystalline toluene solvate form.54. The crystalline toluene solvate of claim 39 , wherein at least 80% of (S)-afoxolaner by weight is a crystalline toluene solvate form.55. The crystalline toluene solvate of claim 39 , wherein at least 70% of (S)-afoxolaner by weight is a crystalline ...

Подробнее
26-05-2016 дата публикации

SALTS OF AZA-BICYCLIC DI-ARYL ETHERS AND METHODS TO MAKE THEM OR THEIR PRECURSORS

Номер: US20160145253A1
Принадлежит:

The present invention relates to salts of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane, to methods for making them or their precursors, to pharmaceutical compositions comprising them, and to their use as medicaments. 1. A salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane wherein said salt is the fumarate , maleate , chloride , phosphate , succinate , or malonate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane.2. The salt according to claim 1 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form.3. The salt according to claim 2 , wherein the salt is characterized by an XRPD pattern substantially the same as the XRPD pattern shown in .4. The salt according to claim 1 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form claim 1 , wherein the mean particle size of the crystals is at least 15 μm.5. The salt according to claim 2 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form claim 2 , and wherein the salt is in substantially pure form.6. The salt according to claim 2 , wherein the salt is the mono-fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-1-aza-bicyclo[2.2.2]octane in crystalline form claim 2 , and wherein the salt has a purity greater than 90 weight %.7. A method for the prevention claim 1 , treatment claim 1 , and/or delay of progression of a disease or condition claim 1 , in which nAChR α7 activation plays a role or is implicated claim 1 , in a subject in need of such treatment claim 1 , which comprises administering to such subject a therapeutically effective amount of a salt as defined in .8. A method for the prevention claim 1 , treatment claim 1 , and/or delay of progression of psychiatric or neurodegenerative ...

Подробнее
25-05-2017 дата публикации

3,5-DICHLORO,4-(3,4-(CYCLO-)ALKOXYPHENYL)- 2-CARBONYLOXY)ETHYL)PYRIDINE DERIVATIVES AS PDE-4 INHIBITORS

Номер: US20170145004A1
Принадлежит: CHIESI FARMACEUTICI S.p.A.

The invention relates to novel 3,5-dichloro,4-(3,4-(cyclo-) alkoxyphenyl)-2-carbonyloxy)ethyl)pyridine compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists, methods of preparing such compounds, compositions containing them and therapeutic use thereof. 4: A pharmaceutical composition comprising a compound of claim 1 , either alone or in combination with another active ingredient claim 1 , in admixture with one or more pharmaceutically acceptable carrier.5. (canceled)6: A method of treating a disease of the respiratory tract characterized by airway obstruction claim 1 , comprising administering the compound according to to a subject in need thereof.7: A method according to wherein the disease of the respiratory tract is selected from asthma and COPD.8: An inhalation device comprising a pharmaceutical composition according to .9: A kit comprising the pharmaceutical composition of and a device which may be a single- or multi-dose dry powder inhaler claim 4 , a metered dose inhaler or a nebulizer. The present invention relates to novel compounds which are both inhibitors of the phosphodiesterase 4 (PDE4) enzyme and muscarinic M3 receptor antagonists. More particularly, the invention relates to compounds of formula (I) as below described, methods of preparing such compounds, compositions containing them and therapeutic use thereof.Chronic obstructive pulmonary disease (COPD) is a respiratory disorder characterized by progressive, not fully reversible, airflow limitation associated with an abnormal pulmonary inflammatory response to noxious particles or gases.For this reason, bronchial relaxation and inflammatory response suppression represent a mechanistic approach to the treatment of COPD that might improve symptoms such as dyspnea, wheezing, chest tightness, cough and mucus secretion, improve health status and reduce exacerbations.Nowadays, the drug therapy options for COPD fall into 2 general classes: ...

Подробнее
14-08-2014 дата публикации

Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV

Номер: US20140228574A1
Принадлежит: Janssen Pharmaceuticals Inc

Disclosed is a process for the preparation of a cinchonidine salt of formula (IV) via an aqueous solution of a racemic 4-hydroxy-1,2-cyclopentanedicarboxylic acid, which is subjected to cyclization without removing water, by the addition of a water-miscible organic solvent to the aqueous solution and, again without removing water, adding cinchonidine to the aqueous-organic solvent solution so as to obtain the cinchonidine salt of the lactone acid. The cinchonidine salt is allowd to crystallize so as to obtain the enantiomerically purified crystalline lactone acid cinchonidine salt (IV). The enantiomerically pure salt is an intermediate in the synthesis of HCV inhibitor compound of formula (I).

Подробнее